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Affected members of the family investigated in this dissertation presented 
with photosensitivity and raised red cell protoporphyrin concentrations, 
indicative of protoporphyria. Further examination of this family revealed 
features that were atypical of erythropoietic protoporphyria. These included a 
highly penetrant disease, disease severity as expressed by more prevalent 
hepatic complications, a preponderance of protoporphyrin in its zinc chelated 
form, a therapeutic response to iron supplementation, and an absence of 
mutations in the ferrochelatase gene or haplotype markers associated with 
erythropoietic protoporphyria. We have reviewed clinical data from this 
family, established a ferrochelatase enzyme assay in our laboratory, and 
shown normal ferrochelatase enzyme activity in affected subjects. This is 
consistent with the atypical features observed, and suggested the presence 
of a disease locus distinct from ferrochelatase. Whilst this study was in 
progress, a collaborative effort between colleagues in Wales and France, and 
our laboratory, led to the discovery of mutations in exon 11 of the X 
chromosome erythroid specific 5-aminolevulinate synthase 2 gene as being 
disease-causing in our family (c.1706-1709 delAGTG) and other families 
abroad. A resultant gain of 5-aminolevulinate synthase 2 function leads to 
increased flux of the haem biosynthetic pathway and culminates in this form 
of protoporphyria. In this work we performed direct sequencing of 5-
aminolevulinate synthase 2 exon 11 as a means of mutational analysis. 
These data, in conjunction with knowledge of the X-linked inheritance 
pattern, have allowed us to offer appropriate genetic counselling and 
prediction of genetic risk to family members. Furthermore, as there was 
reason to justify iron supplementation as a partial treatment strategy, we 
present data showing red cell protoporphyrin fluctuations and ultimate 
reduction during intravenous iron supplementation of 1 family member. 
Results suggest that iron supplementation is a promising and rational 
treatment strategy in this particular form of porphyria. 
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This dissertation investigates the clinical and pathological manifestations of a 
porphyria as encountered in a South African family. Porphyria, as a generic 
term, refers to a heterogeneous spectrum of clinical syndromes resulting 
from the accumulation of substrate proximal to enzyme defects in the haem 
biosynthetic pathway (Anderson et al 2000).  
It is thus appropriate to give a brief overview of porphyrins, haem 
biosynthesis and the disorders resulting from defects therein.  Aspects most 
relevant to later chapters will be afforded emphasis. 
Porphyrins 
Porphyrins consist of four monopyrrole rings joined by methylene bridges, 
forming tetrapyrroles (Figure 1). Porphyrinogens are the hexahydro-reduced 
form. Porphyrins are capable of metal chelation in the centre of the nitrogen 
ring – in the case of ferrous iron incorporation, haem results (Deacon et al 
2008). Magnesium and cobalt chelation achieves the formation of chlorophyll 
and a component of vitamin B12, respectively. Tetrapyrroles are the most 
abundant natural pigments, creating the visual perception of red blood and 
green grass (Heinemann et al 2008). Examples of essential functions haem 
fulfils include oxygen transport, mitochondrial respiration, nitric oxide sensing 
and drug, fatty acid, gluconeogenic and peroxide metabolism.  
Different peripheral substituents occupying positions labelled 1 to 8 (Figure 1) 
in the form of 2 to 3 carbon side chains, with or without carboxyl groups, lend 
unique chemical and biological properties to tetrapyrroles. Their position and 
composition are shown in Figure 2. Importantly, solubility decreases with 
decreasing numbers of carboxyl groups. Variation of the distribution of the 
side chains allows isomer formation, designated by means of Roman 























Fluoresence as a chemical property is important in the study of porphyrins. A 
molecule may be raised to an excited energy state by the absorption of 
radiant energy. Fluorescence occurs when decay from this excited state to 
the ground state occurs, in part by energy transfer to surrounding molecules 
as radiation. Fluorescence always occurs at a longer, lower energy 
wavelength than that which was absorbed (Mathews and van Holde 1990). 
Porphyrins absorb light powerfully around 400 nm (the Soret band). This 
results in an appealing orange-red fluorescence in the range from about 550 
to 650 nm. Peak fluorescence wavelength is influenced by metal chelation 
and peripheral side chain composition. This property of photoreactivity is in 
part responsible for the photocutaneous lesions observed in the porphyrias. 
Iron chelation virtually abolishes fluorescence while zinc shifts peak emission 
to a shorter wavelength and decreases peak intensity. Porphyrinogens, 
lacking conjugated double bonds within the ring, do not fluoresce. They do 
however undergo spontaneous oxidation to porphyrins in vitro (Deacon et al 

















Porphyrin Porphyrinogen Haem 
Figure 1: Fundamental tetrapyrrole structure. Note that the porphyrin ring has 11 







The 8 step biosynthesis of the remarkably complex haem ring in mammals, 
commencing in the mitochondrial matrix with two relatively simple 
compounds - glycine and succinyl CoA, is shown diagrammatically in Figure 
2. 
The first reaction, catalysed by the enzyme 5-aminolevulinate synthase 
(ALAS) (Enzyme Commission number [EC] 2.3.1.37), using pyridoxal 
phosphate (vitamin B6) as co-factor, results in the formation of 5-
aminolevulinic acid (ALA). Importantly, 2 isoenzymes coded by 2 distinct 
genes for ALAS exist: a ubiquitous ‘housekeeping’ isoenzyme is carried on 
chromosome 3 and referred to as ALAS1 (also as ALASN). An erythroid 
specific enzyme referred to as ALAS2 (also as ALASE or eALAS) is encoded 
on the X chromosome (Bishop et al 1981, 1990). These 2 forms of ALAS 
allow the differential regulation of haem synthesis as required by the 2 
primary sites of haem biosynthesis. Indeed, approximately 80% of haem 
synthesis occurs in the bone marrow and about 15% in the liver. 
Interestingly, ALAS2 shows interaction with succinyl CoA synthase within the 
mitochondrial matrix of normoblasts, from which one of its substrates is 
derived (Furuyama and Sassa 2000). In general, regardless of the specific 
site of haem synthesis, ALAS may be considered the main rate-limiting step 
and sets the rate of flux through the pathway (Bloomer 1991, Philips and 
Kushner 2005). 
The second reaction occurs in the cytosol during which 2 molecules of ALA 
condense to form a monopyrrole, porphobilinogen (PBG). Two molecules of 
water are eliminated. This is catalysed by the enzyme ALA dehydratase (EC 
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Figure 2: Diagram of the haem biosynthetic pathway.  Enzymes are numbered 1 - 8 (adapted 
from Deacon et al 2008). 
 Mitochondrion  Cytosol 
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In the next step, hydroxymethylbilane synthase, (EC 2.5.1.61) (also known as 
PBG deaminase) catalyses the condensation of 4 molecules of PBG with the 
release of 4 molecules of ammonia to form hydroxymethylbilane – a linear 
tetrapyrrole. 
During the fourth reaction, uroporphyrinogen (UPG) III synthase (EC 
4.2.1.75) is responsible for closing the tetrapyrrole ring and catalysing 
isomerisation to UPG III, containing 8 carboxyl groups on the side chains. 
Non-enzymatic cyclisation to the I isomer may occur.  
Sequential decarboxylation by UPG decarboxylase (EC 4.1.1.37) through 7, 
6 and 5 carboxyl groups occur to generate the 4 carboxyl 
coproporphyrinogen (CPG) III. The remainder of the pathway, including the 
final haem-producing reaction, occurs within the mitochondrion.  
The sixth reaction consists of the oxidative decarboxylation of CPG III to form 
the dicarboxylic protoporphyrinogen IX via the enzyme CPG oxidase (EC 
1.3.3.3).  
The penultimate step involves the enzymatic oxidation of protoporphyrinogen 
IX to protoporphyrin (PP) IX by protoporphyrinogen oxidase (EC 1.3.3.4). 
Only dicarboxylic porphyrins of the IX series are biologically active (Deacon 
et al 2008). For the purposes of this dissertation all protoporphyrins 
discussed will be assumed to be IX isomers. 
Ferrochelatase (FECH) (EC 4.99.1.1) catalyses the final reaction which uses 
ferrous iron and PP to produce haem. This enzyme is capable of using other 
divalent metals (e.g. zinc) and dicarboxylic porphyrins (e.g. mesoporphyrin) 
as substrates (Deacon et al 2008). This may be exploited in vitro during 
FECH enzyme assay (Li et al 1987). 
 
Substrate competition between iron and zinc during FECH-mediated PP 
chelation means that zinc PP (ZnPP) serves as a sensitive marker of intra-
mitochondrial iron deficiency. Trace amounts of ZnPP are normally formed 
during haem biosynthesis, but during systemic iron deficiency, ZnPP 
accumulates in erythrocytes (Langer et al 1972). 
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Similarly, during diverse states of de facto intra-mitochondrial iron deficiency, 
as occurs in lead poisoning (Lamola et al 1974), the anaemia of chronic 
disorders (Hastka et al 1993), and during accelerated (especially in 
haemolytic anaemia) or ineffective erythropoiesis  (Finch 1994), ZnPP may 
increase.  
Regulation of haem biosynthesis 
ALAS1 is capable of responding to fluctuating hepatocyte haem requirements 
imposed by cellular metabolic pathways. Haem itself, through a number of 
mechanisms, exerts negative feedback on ALAS1 by inhibiting ALAS1 
transcription and import into the mitochondrial matrix (Lathrop and Timko 
1993). In addition, a number of other factors such as drugs, starvation and 
hormonal changes, are capable of inducing ALAS1. These mechanisms are 
not well defined. However, it has been suggested that fasting stimulates 
gluconeogenesis and fatty acid oxidation via induction of peroxisome 
proliferator-activated receptor γ coactivator 1α (PGC-1α). This effect is 
antagonised by glucose and insulin (Handschin et al 2005), and is the basis 
by which both fasting and glucose may play a role in the regulation of 
porphyrin biosynthesis. 
In contrast, ALAS2 transcription is stimulated via erythroid transcription 
factors binding to the promoter region in response to a variety of 
physiological stimuli. The zinc finger transcription factor GATA-1 (named 
after the guanine, adenine, thymine, adenine sequence it binds) has at least 
2 ALAS2-associated binding sites (Surinya et al 1997) while erythroid 
Kruppel-like factor (EKLF) has 1 (Miller and Bieker 1993). These factors 
serve to coordinate haem synthesis relative to the normoblast maturational 
stage and state of globin expression (Nuez et al 1995, Marinkovic et al 2007). 
Similar to ALAS1 regulation, ALAS2 import into the mitochondrial matrix is 
inhibited by haem (Lathrop and Timko 1993). However, the physiological 
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implications of this effect are probably of less importance than in the case of 
ALAS1 (see later under ‘Ferrochelatase, haem and iron synergy’). 
 
Potential toxicity of PP accumulation demands that during erythropoiesis 
ALAS2 activity is capable of matching PP production to iron availability. It is 
believed that appropriate iron delivery to developing normoblasts is achieved 
through translational induction of ALAS2 by means of iron regulatory proteins 
1 (IRP1) and 2 (IRP2). In this seemingly elegant system (for a summary see 
Table 2), intracellular iron deficiency activates iron regulatory proteins (IRPs). 
IRPs are then able to bind to iron response elements (IRE) on mRNA 
transcripts of ALAS2 (Cox et al 1991), ferritin (Theil 1998), the divalent metal 
transporter 1 (DMT1) (Israels and Israels 2002) and the transferrin receptor 1 
(Klausner et al 1993).  
In the case of ALAS2 and ferritin, the IRE is located in 5’ untranslated region 
(UTR) of the mRNA transcript. Binding of the IRP to the IRE results in 
inhibition of translation, signalling a decrease in haem synthesis and iron 
storage until iron availability is restored. This contrasts with the binding of 
IRPs to the transferrin receptor 1 and DMT1 mRNA IRE which occurs in the 
3’ UTR and serves to mediate transcript stability, and hence translation 
followed by transferrin-bound iron uptake and import into the developing 
normoblast. 
IRP1 and IRP2 are homologous proteins. Data generated from murine knock 
out models suggest IRP2 has greater biological utility than IRP1 (Cooperman 
et al 2005). IRP1 has an iron-sulphur (Fe-S) cluster which appears to allow 
iron sensing. Abundant iron leads to cluster assembly, inhibiting its IRE 
binding capabilities and converting IRP1 to a cytosolic aconitase enzyme. 
The intermediary metabolic role of the mitochondrial aconitase isoform in the 
Krebs cycle is well known. In contrast, the function of citrate isomerisation to 
isocitrate in the cytosol of mammals and its relationship with iron status is 
poorly understood (Pitula et al 2004). 
IRP2 does not posses a Fe-S cluster. Instead, intracellular concentrations 
are a function of the rate of IRP2 degradation. Oxidation-induced 
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ubiquitination leads to degradation by the proteosome system. IRP2 is 
oxidised upon haem binding to its haem regulatory motif (Ishikawa et al 
2005). In addition, intracellular iron activates ubiquitination of IRP2 (Guo et al 
1995).  
 
Schranzhofer et al (2006) challenge the applicability of the abovementioned 
‘standard’ model of translational control of erythropoiesis during the final 
accelerated haemoglobinisation phase with its concomitant increased iron 
demand. If the IRP dependent system were able to sense increasing iron 
concentrations, transferrin receptor expression would be down-regulated, 
acquired iron lost to ferritin and iron availability for haem synthesis 
compromised. The “kiss and run” hypothesis (Ponka 1997) offers a partial 
explanation. During terminal erythropoiesis, iron present in vesicles acquired 
by receptor-mediated endocytosis is capable of being targeted directly to the 
mitochondrion without increasing cytosolic iron concentrations. Schranzhofer 
et al (2006) postulate that increased mitochondrial iron import would have a 
similar effect and that during maximal haemoglobinisation, ALAS2 mRNA 
increases disproportionately to IRPs thus obviating any requirement for 
cytosolic IRP concentrations to decrease in order to enhance ALAS2 
translation.  
 
In contrast to the basic tenets of the theory used to explain the regulation by 
the IRP system, and despite the postulate that ALAS2 expression may not be 
dependent on iron signaling through the IRP system (Schranzhofer et al 
2006), it has been shown that iron is capable of increasing haem synthesis 
through the IRP system during iron-deficient states. However, during iron-
replete states, additional iron does not stimulate haem synthesis (Ishikawa et 
al 2005). This may serve to prevent excess haem synthesis in genetic 
disorders of iron overload, and account for the rapid reticulocyte response 
commonly observed during the reversal of iron-deficient states.   
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Further coordination of erythroid mass, haem synthesis and iron metabolism 
in defending oxygen delivery is attained by erythropoietin-induced IRP1 
activation, leading to increased normoblast transferrin receptor expression 
(Weiss 1997). Secretion of erythropoietin is under control of the von Hippel-
Lindau / hypoxia-inducible transcription factor pathway, which is capable of 
sensing oxygen tension via an oxygen-requiring, iron-dependent, prolyl 
hyroxylase system (Elbert and Brunn 1999). This system contributes to the 
regulation of iron absorption and availability via inhibition of hepcidin and 
upregulation of ferroportin (Peyssonnaux et al 2007). Ultimately, ALAS2 
transcription is also regulated by the activation, and enhanced transcription 
of, GATA-1 by erythropoietin through the Janus kinase 2 and signal 
transducer and activator of transcription (STAT) pathways (Dalyot et al 1993, 
Zhao et al 2006). Erythropoietin and GATA-1 are powerful survival stimuli to 
normoblasts (Israels and Israels 2002).  
The porphyrias 
The porphyrias result from partial deficiencies of specific enzymes in the 
haem biosynthetic pathway (Anderson et al 2000). 
Precursor accumulation has the potential to cause an acute porphyric attack. 
Conversely, porphyrinogen or PP (tetrapyrrole) accumulation correlates with 
photosensitivity, a less acute symptom. These are the two cardinal 
syndromes in the porphyrias. Precursor and proximal, more water-soluble 
tetrapyrroles are excreted in the urine. More distal, less water-soluble 
tetrapyrroles are excreted via bile and hence the stool. In the erythropoietic 
porphyrias, porphyrin accumulation is primarily within erythrocytes (Deacon 
et al 2008).   
The acute attack of porphyria represents a medical emergency in which 
confident laboratory diagnosis or exclusion is essential to direct appropriate 
treatment (Anderson et al 2000). There are several theories (Meyer et al 
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1998) relating to the pathogenesis of the acute attack. One such hypothesis 
states that ALA (or a related metabolic product) may act as a neurotoxin 
(Solis et al 2004). Such an effect may relate to the structural resemblance of 
ALA to neurotransmitters such as γ-aminobutyric acid (GABA). Furthermore, 
succinylacetone, which accumulates in hereditary tyrosinaemia type I, 
resembles ALA and is capable of competitive inhibition of ALA dehydratase. 
Lead is another well known and potent inhibitor of ALA dehydratase (Sassa 
2006). These toxins share an ability to induce a crisis very similar to the 
acute porphyric attack. 
 
Interestingly, not all the cutaneous porphyrias exhibit identical skin 
involvement. The photosensitivity in erythropoietic protoporphyria typically 
manifests as an acute photoreaction accompanied by burning and pruritis 
within minutes of sun exposure. This, in time, may lead to subtle but typical 
chronic changes such as waxy skin thickening and mild grooving, particularly 
over the dorsal surfaces of the knuckles and the bridge of the nose. This is in 
contrast with the typical blisters, pigmentary changes and scarring in sun 
exposed areas seen in variegate porphyria and porphyria cutanea tarda. The 
underlying pathology is thought to be due to circulating or skin-entrapped 
photoreactive porphyrins which are excited by light in the Soret band (Smith 
et al 1990). Conventional non-porphryric sunburn occurs after exposure to 
light of a wavelength around 300 nm. 
Transfer of energy from porphyrin to oxygen molecules occur with 
subsequent generation of reactive oxygen species and lipid peroxidation. 
Complement activation and degranulation of mast cells ensue, leading to an 
acute inflammatory cascade. Fibroblast response leads to scarring (Lim 
1989).  
X-linked sideroblastic anaemia (XLSA) results in anaemia and iron overload 
and is due to loss of function mutations in the first enzyme of haem 
biosynthesis in erythroid cells, ALAS2 (Sadlon et al 1999). As would be 
expected, porphyrin accumulation and porphyria does not result. Mututions in 
ALAS1 have not been described.  
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A brief outline of the porphyrias and other related disorders associated with 
haem biosynthesis is shown in Table 1. 
 
Table 1: Summary of the disorders resulting from enzymatic defects in 
the haem biosynthetic pathway (modified from Sassa 2006) 
Enzyme defect Disorder Main clinical 
effects 
Aetiology 










Autosomal recessive  
(enzyme may be 


















































As the family of interest in this dissertation presented with a biochemical 
picture of atypical erythropoietic protoporphyria (EPP), EPP will be discussed 
in more detail. 
EPP results from a partial deficiency of FECH. Autosomal dominant 
inheritance, usually with a primary FECH mutation in trans to a low-
expression IVS3-48C polymorphism, is most common (Gouya et al 2002). 
This form of inheritance, although not strictly autosomal dominant, is referred 
to as ‘autosomal dominant’ or ‘autosomal pseudodominant’. The IVS3-48C 
polymorphism increases the use of an aberrant splice site. Approximately 3% 
of cases are due to true autosomal recessive inheritance (Gouya et al 2006). 
Acquired EPP has been reported in the setting of haematological malignancy 
and cytogenetic FECH deletions associated with clonal expansion of FECH 
deficient bone marrow cells (Aplin et al 2001, Bharati et al 2006, Goodwin et 
al 2006).  
The biochemical hallmark of EPP is raised red cell PP which tends to be in 
the free (i.e. no bound metal) form – due to an inability of the FECH enzyme 
to metabolise substrate. Causes of raised ZnPP (see page 23-24), are 
generally related to decreased iron availability as opposed to FECH 
deficiencies per se.  
Unique clinical features of EPP include the acute nature of the 
photosensitivity, disease onset in infancy, and the possibility of liver disease 
developing as a direct result of the porphyria (Todd 1994).  
Manifest liver disease is a relatively rare complication, occurring in 
approximately 3% of EPP patients (Anstey and Hift 2007). Free PP (but not 
ZnPP) is capable of diffusing out of red cells, with reticulocytes containing 
proportionally more PP than mature red cells (Piomelli 1975). PP is excreted 
into bile by the liver and undergoes extensive enterohepatic circulation due to 
its lipophilic nature. Increasing PP concentrations may lead to PP insolubility, 
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cholestasis and cholelithiasis. Hepatocyte injury is manifest with inflammation 
which may eventually lead to cirrhosis (Poh-Fitzpatrick 1986). In the terminal 
phase of EPP-related liver disease, increasing cholestasis impairs hepatic 
PP excretion. Oxidative stress-induced haemolysis occurs with increasing PP 
concentrations, driving erythropoiesis and increasing PP load presented to 
the liver - propagating a cycle of clinical deterioration (Key et al 1992, Anstey 
and Hift 2008). 
The precise pathogenesis of hepatopathy in EPP is not fully understood, but 
an autosomal recessive inheritance pattern, a family history of EPP-related 
liver disease and additional non-EPP related liver insults (e.g. ethanolic or 
viral injury) are risk factors or associations for hepatic complications 
(Nordmann 1992, Anstey and Hift 2008). 
Major structural FECH alterations have been associated with developing 
hepatopathy but on the other hand the liver disease may simply be a function 
of particularly marked PP accumulation (Bloomer et al 1998). One case 
report describes aggravation of EPP disease severity leading to hepatopathy 
as a consequence of hypermethylation of the FECH promoter (Onaga et al 
2004).   
While photosensitivity may be painful, distressing or disrupt an affected 
individual’s lifestyle (Todd 1994), liver disease may be fatal.  An 
understanding of the factors culminating in liver disease represents (one of) 
the holy grail(s) of EPP-related research. 
 
Ferrochelatase, haem and iron synergy 
 
Ponka (1999) indicates that erythroid iron acquisition and metabolism is often 
neglected when haem biosynthesis is considered. He complains of “….heme 
pathway schemes, which, with overwhelming majority, show iron 
‘mysteriously’ appearing in mitochondria, always ready to be grasped by 
ferrochelatase”.  
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Iron is absorbed into developing erythroid cells by receptor-mediated 
endocytosis of the iron-transferrin complex bound to the transferrin receptor. 
The endosome is acidified leading to release of iron from transferrin. 
Transport across the endosomal membrane is effected by DMT1 - the same 
transporter which is responsible for moving iron across the apical border of 
the enterocyte in the gut (Ponka et al 1998).   
Haem deficiency, signalling though the IRP2 system, serves as a potent 
stimulant to transferrin-mediated iron uptake by erythroid cells (Ishikawa et al 
2005). In an experiment investigating product (haem) inhibition during haem 
synthesis, it was found that iron presented to reticulocytes as a lipophilic 
conjugate, negates any inhibitory effect of haem. When transferrin is used as 
an iron carrier (rather than the lipophilic conjugate), inhibition does occur, and 
radiolabelled glycine is incorporated into PP but not into haem (Ponka et al 
1973). This is consistent with failure of iron delivery to erythroid cells when 
excess haem is present (Ponka and Schulman 1985).  
The power of erythron iron acquisition (such as would be required for 
physiological haem production) is illustrated by a simple calculation. Assume 
normal diferric transferrin iron of ~ 3 µmol/L (only diferric transferrin can 
deliver iron effectively to the transferrin receptor) (Ponka 1998) and a normal 
whole blood haemoglobin of ~ 15 g/dL = 150 g/L. At a haematocrit of 50%, 
red cell haemoglobin = 300 g/L. The molecular weight of a haemoglobin 
monomer is ~ 15 000. Thus red cell haemoglobin monomer concentration = 
0.02 mol/L = 20 mmol/L. Each monomer chelates one iron atom, thus a ~ 
7000 fold difference between serum and erythron iron concentrations exists. 
Mammalian FECH is nuclear encoded. After synthesis in the cytosol it is 
targeted to the inner mitochondrial membrane via a leader sequence where it 
functions as a homodimer (Karr and Dailey 1988). FECH contains a Fe-S 
complex near its carboxy (C)-terminus. The Fe-S cluster is not involved in 
binding iron as substrate for FECH catalysis (Ferreira 1999). Instead, the Fe-
S cluster serves to facilitate FECH dimerisation (Dailey et al 2000). 
Furthermore, it enables intracellular iron concentrations to influence FECH 
expression, suggesting an iron-sensing capability, and serving to coordinate 
FECH activity and substrate availability (Taketani et al 2000).  
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A recent report described decreased erythroid FECH activity and intracellular 
FECH concentrations during intracellular iron deficiency, in genetic disorders 
of Fe-S assembly and during oxidative stress (Crooks et al 2010).  
Haem is reported to inhibit FECH activity in a non-competitive manner 
(Dailey and Fleming 1983). This may function physiologically as a negative 
feedback system on FECH activity. 
X-linked sideroblastic anaemia and ataxia (ASAT), resulting from a mutation 
in the adenosine triphosphate binding cassette 7 transporter (ABC7), is 
characterised by elevated free PP concentrations (Allikmets et al 1999). This 
disorder is a different entitity from the more well-known XLSA previously 
mentioned. Taketani et al (2003) propose that ABC7 is involved in the 
formation and maintenance of the FECH Fe-S cluster. In addition, ABC7 
exports Fe-S clusters for use by other cytosolic proteins.  
Mitochondrial iron import in erythroid tissue is achieved by a transporter 
termed mitoferrin (Shaw et al 2006a). Mitoferrin forms a complex with FECH, 
which may facilitate the coordination of mitochondrial iron import and haem 
biosynthesis (Chen et al 2010). It has been proposed that aberrant splicing of 
mitoferrin mRNA may be capable of producing a rare variant form of 
protoporphyria (Shaw et al 2006b).  
Although haem deficiency is not necessarily part of the porphyria syndrome, 
a mild anaemia with hypochromic and microcytic features is frequently found 
in EPP. This suggests that a mild defect in haem production might exist in 
erythroid tissue in EPP. Iron parameters, in the absence of other factors such 
as blood loss, are normal (Holme et al 2007) and bone marrow iron store 
assessment reveals stainable normoblast iron. However, ring sideroblasts 
have been reported in human EPP (Rademakers et al 1993). Interestingly, 
ring sideroblasts were not present in the murine EPP model (Lyoumi et al 
2007). 
It is of note that the only vehicles for iron export from mitochondria are haem 
and Fe-S clusters (Huang et al 2009). 
It may be useful to conclude this discussion of the relevance of iron 
metabolism to the haem biosynthetic pathway with a summary (Table 2). 
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Table 2: Relative and simplified physiological changes in normoblast 
effector proteins associated with varying intracellular iron concentrations 
Effector protein Iron-deficient normoblast Iron-replete normoblast 
IRP Increase Decrease 
Transferrin receptor 1 Increase Decrease 
DMT1 Increase Decrease 
Ferritin Decrease Increase 
ALAS2 Decrease Increase 
FECH Decrease Increase 
Laboratory testing in erythropoietic 
protoporphyria
As this dissertation focuses on an atypical EPP family, and initially in 
establishing a diagnosis, it is appropriate to review conventional approaches 
in establishing such. 
Biochemical testing for EPP focuses on detection of elevated concentrations 
of PP in the blood. For example, biochemical diagnosis of EPP can be made 
by plasma fluorescence scanning with excitation at 405 nm. A characteristic 
emission peak occurs at 632 nm, assisting in the differentiation of EPP from 
other cutaneous porphyrias such as variegate porphyria (emission peak at 
625 nm) and porphyria cutanea tarda (emission peak at 618 nm) (Poh-
Fitzpatrick 1980, Deacon and Elder 2001).  
Quantitative analysis may be performed on extracted porphyrin esters or 
porphyrin acids. This may be followed by a variety of chromatographic 
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methodologies with fluorescence detection including high performance liquid 
chromatography (Deacon et al 2008). These methods have the potential to 
quantify other porphyrins in addition to PP (Day et al 1978). Alternatively, PP 
may be quantified fluorometrically against a standard (Deacon and Elder 
2001), or even qualitatively by simple visual inspection of a red cell methanol 
extract under ultraviolet light. However, although commonly performed, the 
latter method is insensitive and should only be used if preferred 
methodologies are not available.  Acidic reagents or extraction media used in 
the above methods dissociate zinc from ZnPP, thus converting ZnPP to free 
PP and measuring total PP. When attempting to measure the 2 individual PP 
species, non-acidic reagents such as acetone should be used. 
Qualitative determination of the relative contributions of ZnPP and free PP to 
total PP concentrations may be performed by simple inspection of a 
fluorescence emission spectrum, typically with excitation at 420 nm.  ZnPP 
has a main emission peak at 588 nm while that of free PP lies at 632 nm. 
Two caveats apply – ZnPP has less specific fluorescence than free PP and 
ZnPP has a subsidiary emission peak at 636 nm, thus boosting the apparent 
fluorescence of the free PP peak at 632 nm (Hart and Piomelli 1981). The 
finding of a dominant peak at 588 nm tends to rule against EPP (because of 
probable elevated ZnPP) while a single peak at 632 nm is highly suggestive 
of EPP (Deacon and Elder 2001). In order to obtain ZnPP as a percentage of 
total PP by emission fluorescence measurement an equation has been 
developed (Hart and Piomelli 1981). This involves fluorescence 
measurement at 588 nm and 618 nm (the isosbestic point – where equal 
concentrations of ZnPP and free PP will exhibit identical fluorescence 
intensity).  
Fluorocytes are red cells packed with PP, endowing them with fluorescence. 
This may be visualised with a microscope equipped with a light source 
capable of excitation in the Soret band (Rimington and Cripps 1965). 
Due to the insolubility of PP, and because PP does not cause secondary 
inhibition of porphobilinogen deaminase as may occur in variegate porphyria 
(Meissner et al 1991), urine precursors and porphyrins are not elevated in 
EPP. This is a consideration in the formulation of a differential diagnosis. 
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Stool porphyrin analysis may show the presence of PP (reflecting degraded 
red cells) but false positives from bacterially degraded haem, gastrointestinal 
haemorrhage, and other factors may occur.  
Considering the inherited nature of EPP, it follows that genetic testing may be 
appropriate and may be conducted using standard molecular biology 
techniques. However, it must be noted that the majority of the mutations in 
the FECH gene causing EPP are heterogeneous (Rufenacht et al 1998) and 
testing must be individualised for most families. This being said, DNA-based 
testing is a particularly efficient way of diagnosis in families where the 
mutation causing the porphyria is already known, or a degree of homogeneity 
may be expected. Indeed, due to the unique history of the early South African 
immigrant population, founder mutations often predominate. Among patients 
affected by EPP in South Africa, the 757_761delAGAAG five base pair 
deletion in exon 7 of FECH is a particularly common disease-causing 
mutation (Parker et al 2008). This deletion causes a frameshift mutation, 
resulting in a truncated FECH protein. As found elsewhere (Gouya et al 
2006), the IVS3-48C EPP low-expression polymorphism is common in South 
Africa among patients with EPP and in control groups (Parker et al 2008). 
Thus, in EPP families, testing the unaffected parent for the IVS3-48C 
polymorphism has clinical utility in predicting clinical disease expression in 
the progeny (Deacon et al 2008).  
Due to varying disease penetrance, DNA-based results should be interpreted 
within the clinical context. Furthermore, porphyrin biochemistry should be 













The family of interest (family EPP8) in this dissertation was identified during a 
study conducted by the Lennox Eales Porphyria Laboratories of the 
University of Cape Town (UCT) from 2004 to 2007 (Parker et al 2008).  
In that study, single-stranded conformational polymorphism analysis, direct 
sequencing of abnormalities, restriction digestion to screen for specific 
mutations, and haplotyping were used to genotype FECH in a South African 
cohort of EPP and control subjects. The family investigated and 
characterised further in the present dissertation was designated ‘family 
EPP8’. 
Although initially assumed to have EPP, Parker et al (2008) noted several 
atypical features which served to distinguish family EPP8 from other patients 
with EPP in that study. 
Strikingly, mutations in the FECH gene were not detected. Haplotype 
analysis revealed that the porphyria in this family did not segregate with 
haplotype markers associated with EPP. Clinically manifested disease 
transmission from parent to child occurred between generations II and III 
(Figure 3, Chapter 3). This contrasts with conventional EPP inheritance, 
where the unique requirement for the IVS3-48C allele to be in trans to the 
primary mutation, causes generations to be ‘skipped’. Unusually, 
photosensitivity was highly penetrant and hepatopathy was severe with 2 out 
of 6 affected subjects manifesting severe liver disease. One of these had 
died of hepatic complications many years previously, while another 
deteriorated during the course of this study. Biochemical testing showed a 
preponderance of ZnPP, as opposed to free PP usually found in EPP.  
Finally, iron treatment was noted anecdotally to decrease photosensitivity.  
 
Discussion with investigators in Wales (University of Cardiff) and France 
(Centre Francais des Porphyries), revealed a very similar if not identical 
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disease entity in some atypical EPP patients in those countries. International 
collaboration was established. Several hypotheses emerged and aspects of 
these formed the basis of the investigation described here. The present study 
was conducted at Groote Schuur Hospital (GSH), Cape Town in 2008 to 
2009. 
 
Initial aims and objectives were proposed and pursued. Additional aims and 
objectives were formulated in principle, and developed as the project 
proceeded, guided by emerging and evolving information. In addition, this 
study and dissertation should best be considered as a part component of a 




1. Characterise the clinical and biochemical features of porphyria found in 
family EPP8.   




1. Following ethics approval, establish clinical contact with family EPP8. 
Collect additional clinical information and blood samples. Collate and 
review all available clinical and biochemical data. 
2. Transform subject and control lymphocytes with Epstein Barr Virus (EBV) 
to generate immortalised lymphoblast cell lines as tissue medium for 
FECH enzyme assay.   
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3. Establish a FECH enzyme assay locally (not previously performed in
South Africa) using a published method. Measure EBV transformed
lymphoblast (EBVTL) FECH activity in subjects and controls.
Supplementary aims 
1. In the case of abnormal FECH activity, establish level and nature of
defect.
2. In the case of normal FECH activity, explore alternative gene loci and/or
explanations. However, it should be noted that finding an alternative gene
locus and/or disease mechanism may be beyond the scope of a MMed
project.
3. Develop and implement rational treatment strategies based on study
findings and relevant to this particular family. This would be in addition to
a consideration of the existing guidelines for the management of EPP.
Supplementary objectives 
1. Abnormal FECH activity with normal genotyping would suggest the utility
of the following investigations:
a. Measurement of FECH mRNA concentrations to investigate
epigenetic disease mechanisms (e.g. hypermethylation of the
FECH promoter as described by Onaga et al 2004). Quantitative
reverse transcriptase polymerase chain reaction (RT PCR) of
FECH mRNA could be used to measure relative FECH
transcription in subjects and controls against a reference
‘housekeeping’ gene such as beta-actin.
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b. Quantification of FECH protein expression by Western blot 
analysis. 
2. Normal FECH activity would imply that an alternative locus or mechanism 
is the cause of the disease. Iron transporters would be suitable alternative 
candidate genes. Potentially, other genes or proteins in the haem 
biosynthetic pathway, either synthetic or regulatory, may be involved in 
the pathogenesis of the porphyria in family EPP8.  
3. Potentially explore novel treatment strategies based on knowledge gained 
of the molecular pathogenesis of the porphyria.  
4. Report back to family EPP8 on findings of this project and offer 
appropriate counselling and assessment of risk based on clinical, 
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This chapter provides clinical information from family EPP8, to illustrate the 
background to the investigations described in Chapters 4 - 6.  
Family EPP8 
The family is of Jewish descent, generation I having arrived in South Africa 




Eales et al (1978) gives a detailed account of the clinical presentation of 
patient EPP8.12. At the age of 29 (1971), his liver disease was investigated 
and a liver biopsy showed cirrhosis. He, along with his 2 siblings, was 
Figure 3: Genogram of family EPP8 showing 4 generations. Squares represent 
males and circles, females. A strike through represents a deceased individual - 
1972 and 2008 for subjects EPP8.12 and EPP8.2, respectively. A filled symbol 
implies disease manifestation while a shaded symbol refers to uncertain disease 
manifestation. An unfilled symbol implies an asymptomatic state. Asymptomatic 
subjects who were not investigated are not numbered. 
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diagnosed with EPP. Although all 3 siblings reported photosensitivity typical 
of EPP since early childhood (5 – 6 years of age), subject EPP8.12 was 
unique in the scarring and severity of his skin symptoms. In 1972 he 
presented to GSH with liver failure. Despite all available therapy, he died of 
massive haemorrhage from oesophageal varices secondary to portal 
hypertension. 
Although the genogram in Figure 3 shows clear evidence of an inherited 
disease coupled with a high degree of penetrance in generation II and III, the 
exact mechanism of inheritance is not apparent. In 1971, subject EPP8.13 
had raised faecal porphyrins and was thought to be a carrier. She remained 
completely asymptomatic and was described as being “able to sit in the sun 
for hours”. 
Subject EPP8.2 was noted to have a firm hepatosplenomegaly and 
underwent open liver biopsy in 1975. This resulted in post operative 
haemorrhage requiring intensive care admission. Histology showed early 
bridging fibrosis and PP pigment. Subject EPP8.6 was also found to have 
hepatosplenomegaly, albeit less than in her brother. She did not have a liver 
biopsy. At the time, thrombocytopenia was noted in subjects EPP8.12 and 
EPP8.2 (23 and 89 x 109/ L, respectively). 
The presence of glucose 6 phosphate dehydrogenase (G6PD) deficiency in 
this family was established by Eales et al (1978). In that study, subjects 
EPP8.12 and his brother EPP8.2 were shown to have deficient G6PD 
activity. Their sister, subject EPP8.6, manifested as a G6PD deficiency 
carrier, consistent with X-linked recessive transmission. 
Contact was re-established with family EPP8 during the study on EPP in 
South Africa (Parker et al 2008). Red cell PP concentration was measured in 
2005 and again in 2008/9 in available subjects (Table 3 and Appendix C). 
The results, in conjunction with symptoms (photosensitivity and avoidance of 
sun exposure, e.g. wearing of gloves while driving), were used to define the 
syndrome of EPP. The preponderance of ZnPP in family EPP8, in contrast to 
the free PP observed in typical EPP, was also noted (Appendix D) and an 
example is shown in Figure 4.  
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Table 3: Red cell PP concentration (conc) in family EPP8 (normal red 
cell PP < 2000 nmol/L) 
Subject Conc 2005 (nmol/L)   Conc 2008/9 (nmol/L) Photosensitivity 
EPP8.1 5644 24 083 Moderate 
EPP8.2 11 083 72 042 Severe 
EPP8.3 Not measured 970 None 
EPP8.4 9343 48 750 Severe 
EPP8.5 8138 Not measured Mild 
EPP8.6 27 285 10 140 Moderate 
EPP8.7 195 Not measured None 
EPP8.8 97 Not measured None 
EPP8.9 95 Not measured None 
EPP8.10 Not measured 813 None 
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Figure 4: Fluorescence emission scans of red cell porphyrin extracts with excitation at 
420 nm. Relative fluorescence units (RFU) are plotted vertically against emission 
wavelength. On the left is the spectrum obtained from subject EPP8.1 with prominent 
ZnPP peak at 588 nm. On the right, note the dominant peak at 632 nm seen in an 
unrelated patient with typical EPP, indicative of predominantly free PP. Courtesy of Ms 










In addition, routine biochemical and haematological parameters were 
measured in symptomatic subjects (Table 4). 
Table 4: Age, biochemistry and haematology results from selected 
members of family EPP8 taken at baseline investigation in 2008/9. 
Reference ranges are indicated in brackets. 
Subject EPP8.1 EPP8.2 EPP8.4 EPP8.5 EPP8.6 
Age 25 63 39 45 68 
Haemoglobin     
(10.5-13.5 g/dl: females, 
13.0-17.0 g/dl: males) 
12.1 11.0 12.1 13.9 12.3 
Mean red cell volume 
(81-96 fl) 95 96 79 86 79 
White cell count  
(4.0-10.0 x109/L) 6.0 4.9 5.9 5.8 3.9 
Platelets (140-420 x 109/L) 172 38 127 158 63 
Albumin (37-52 g/L) 43 43 38 47 46 
Total bilirubin 
(2-20 µmol/L) 38 38 11 12 15 
Alkaline phosphatase 
(40-120 U/L) 43 89 34 62 45 
Gamma glutamyl 
transferase (5-43 U/L) 41 244 20 18 28 
Alanine amino transferase 
(10-32 U/L) 21 152 33 20 26 
Asparate amino 
transferase (10-32 U/L) 19 179 32 20 26 
International normalised 
ratio (INR) 0.9 1.3 0.9 1.0 1.0 
Iron  (10-30 µmol/L) 11 14 5 18 12 
Transferrin (2.0-3.6 g/L) 3.2 2.9 3.0 2.7 2.5 
Transferrin sats (20-50%) 14 19 7 27 18 




Subject EPP8.2 manifested with accelerated disease during 2008, leading to 
intensive investigation which yielded information which will be presented here 
to illustrate the progression of his disease. It should be noted that much of 
the biochemistry and pathology described here for subject EPP8.2 may 
reflect the porphyria against a background of decompensated liver disease, 
which may be different to that observed in a patient with normal liver function. 
 
Presenting features and investigation 
Subject EPP8.2 was able to lead a productive and relatively asymptomatic 
life until the middle of 2007 when he noted increasing photosensitivity and 
right upper quadrant pain. At his initial evaluation at GSH in December 2007 
he was found to have mild hyperkeratosis of the hands and face, 
hepatosplenomegaly and modest ascites. Blood results were as presented in 
Table 4. His peripheral blood contained fluorocytes (Figure 5). Previously, in 
November 2007, a bone marrow biopsy had been performed at another 
centre in view of ongoing thrombocytopenia and had excluded a 
myelodysplastic syndrome. Increased megakaryocytes were present (Figure 
6), compatible with peripheral consumption, due to e.g. hypersplenism 














Figure 5: Fluorocytes (red) are visible on an unstained peripheral slide of 
patient EPP8.2 at 100x original magnification (mag) on the left and 500x mag on 
the right. Excitation wavelength ~ 400nm with an Olympus BX41 fluorescence 
microscope. Photograph taken with the help of Ms G Schutte, Cytogenetics, 








Figure 6: Haematoxylin and eosin stained section of a bone marrow biopsy from 
patient EPP8.2 shows increased megakaryocytes (100x mag) on the left, and at 
500x mag on the right. The tissue was provided by and photographed with the 
permission of Prof P Jacobs (Constantiaberg Medi-Clinic, University of 
Stellenbosch and Tygerberg Hospital). 
Figure 7a: Prussian blue staining of a particle obtained during bone marrow 
aspiration of patient EPP8.2 (100x mag). Note decreased iron stores. A normal 
control showing stainable iron is not shown here. The tissue was provided by 
and photographed with the permission of Prof P Jacobs (Constantiaberg Medi-




































Figure 7b: Prussian blue staining of bone marrow trephine biopsies from a 
normal control (above) and from patient EPP8.2 (below) is shown (both at 
500x mag). Note the presence of iron in the normal control biopsy but 
decreased stainable iron in the biopsy from patient EPP8.2. The tissue from 
patient EPP8.2 was provided by and photographed with the permission of Prof 







The precise cause of the iron deficiency was not apparent and a gastroscopy 
did not reveal oesophageal varices. Thrombocytopenia may have been 
contributory. 
An abdominal computed tomography (CT) scan was performed in order to 
investigate ongoing abdominal pain (Figure 8). The gallbladder appeared 
abnormal. Chronic cholecystitis was diagnosed and it is likely that calculi 
were composed of PP. He later developed several episodes of cholangitis 







Figure 8: Transverse abdominal CT scan with intravenous contrast of patient 
EPP8.2 showing features of portal hypertension. Note the splenomegaly, the 
dilated portal and splenic veins, and the abnormal gallbladder. Ascites is not 
apparent, as the images were taken after paracentesis. (L = liver, S = spleen, K = 
kidney, A = aorta, IVC = inferior vena cava, PV = portal vein, SV = splenic vein, G 
= left gastric vein, P = pancreatic neck vein).  Courtesy of Prof S Benningfield, 
Department of Radiology, UCT and GSH. 
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Treatment and progression of patient EPP8.2 
Ongoing standard treatment of protoporphyric liver disease included 
treatment with oral ursodeoxycholic acid, c33holestyramine, intravenous 
haem arginate and iron (see Chapter 6). A more definitive management plan 
directed at the predominant problem of portal hypertension and liver cirrhosis 
was proposed. The plan included the following sequential procedures: 
1. Reduction in portal pressure by transjugular intrahepatic 
portosystemic shunt (TIPSS) insertion (Figure 9) 
2. Cholecystectomy to remove a possible source of sepsis 
3. Liver transplantation. 
TIPPS insertion on 16 July 2008 caused a dramatic but temporary 
improvement in symptomatology, as evidenced by a marked decrease in 
ascites, a reduction in abdominal discomfort, and a subjective sense of 
recovery.  
A liver biopsy (Figure 10) was performed at the time of TIPPS insertion and 
confirmed severe, long-standing PP induced liver damage. 
Hyperammonaemia (Figure 11) and encephalopathy, known complications of 
TIPSS insertion, were not clinically significant problems.  
Ascites, previously requiring the drainage of 3 - 7 litres of peritoneal fluid 








































Figure 10: Haematoxylin and eosin stained section of liver tissue from patient 
EPP8.2. On the left (500x mag), ballooning degeneration of hepatocytes and 
plugging of bile ducts by mahogany coloured pigment casts are seen. Smaller 
quantities of pigment are visible within hepatocytes. On the right (1000x mag), 
polarizing microscopy shows yellow to red birefringence of PP with a Maltese 
cross appearance. Courtesy of Dr HT Wu and Associate Prof H Wainwright, 
Division of Anatomical Pathology, UCT and NHLS GSH. 
Figure 9: Image produced during fluoroscopically guided TIPSS placement in 
patient EPP8.2. The stent traverses the hepatic vein (HV), the liver parenchyma 
and the portal vein (PV). A catheter is temporarily located within the stent. 
Courtesy of Prof S Benningfield, Department of Radiology, UCT and GSH. 
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On 21 August 2008 the patient was admitted to the intensive care unit in a 
critically ill state with renal and respiratory failure. After 11 hours of 
incubation, a blood culture specimen taken on admission yielded gram 
negative bacilli which were identified as extended spectrum beta lactamase 
producing Klebsiella pneumonia organisms. 
During the final phase of his illness, his PP fluorescence shifted from a bi-
peaked fluorescence emission scan associated with the atypical porphyria as 
encountered in family EPP8 (Figure 4, left), to a pattern more typical of that 
associated with EPP (resembling Figure 4, right), containing ~ 90% free PP.  
It is thought that the septic focus, from where the septicaemia originated, was 
the diseased gallbladder, or alternatively the TIPSS. Leucopenia (Figure 12), 
predominantly a neutropenia, may have resulted from direct myelosupression 
secondary to sepsis. 
Figure 11: Changes in plasma ammonia concentration in patient EPP8.2 over 
time. Baseline plasma ammonia remains elevated. Concentrations rise 
modestly, and then stabilise following TIPSS insertion. During septicemia and 
multi organ failure, ammonia concentrations rise precipitously as a 
consequence of impaired liver function. Upper and lower limits of the 

























Despite all available supportive management in an intensive care setting, 
including appropriate antibiotics, ventilation and haemodialysis, patient 
EPP8.2 died on 8 September 2008 from multi-organ failure secondary to 
overwhelming sepsis. 
 
An autopsy was not performed. 
Figure 12: Changes in peripheral blood white cell count over time during 
septicemia in patient EPP8.2. Initial marked leucopenia during 
septicemia changes to leucocytosis with filgrastim (Neupogen; 
recombinant human granulocyte colony stimulating factor) treatment. 





Ferrochelatase enzyme assay 
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As outlined in Chapter 2, determining FECH enzyme activity in family EPP8 
was an important first step in establishing a diagnosis and elucidating a 
pathogenic mechanism. Indeed, a divergence in proposed investigation 
objectives was dependent on this measurement - normal activity would 
suggest that an alternative disease locus should be sought; in the case of 





In vivo, FECH catalyses the chelation of ferrous iron by PP to form haem 
(Figure 2). Zinc may act as an alternative substrate to form ZnPP. In vitro, 
FECH is capable of using alternative dicarboxylic porphyrins such as 
mesoporphyrin or deuteroporphyrin as substrates. As indicated in Chapter 1, 
PP and ZnPP fluoresce, but haem does not – this is therefore the basis for 
many FECH enzyme assays. Only iron in its ferrous (reduced/Fe2+) state can 
act as substrate for FECH, necessitating anaerobic assay conditions. Zinc as 
substrate is not prone to oxidation, and enzyme activity for zinc chelation 
may be measured aerobically.  
 
FECH activity has been measured using a variety of techniques. Porra and 
Jones (1963) used the pyridine haemochromogen procedure to measure 
FECH activity. This assay is said to be less sensitive than fluorometric 
methods (Li et al 1987).  
Sassa et al (1982) measured PP substrate disappearance by fluorimetry 
during incubation for 24 hr as a measure of FECH activity. Further 
information was gained by including either iron chelation or supplementation. 
However, a large excess of porphyrin is used during the incubation and this 
is reported to result in poor sensitivity (Li et al 1987).   
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In another technique, radiolabelled iron 59Fe2+ as substrate provides greater 
sensitivity. Difficulties have been encountered during the separation of free 
59Fe2+ from the 59Fe labelled haem at the end of the reaction (Bloomer and 
Morton 1982). 
The FECH assay described and used in this dissertation was a direct 
fluorometric measurement of FECH-catalysed zinc mesoporphyrin (Zn meso) 
product formation, using mesoporphyrin and zinc as substrates. This method 
was based primarily on the assay described by Gouya et al (2006). Earlier 
work was an additional source of information (Li et al 1987, Rossi et al 1988). 
In our assay, EBVTL served as a tissue source of FECH. Li et al (1987) 
originally used homogenated rat liver as tissue. Rossi et al (1988) and Gouya 
et al (2006) used lymphocytes isolated from peripheral blood. 
As our objective was to establish a FECH assay and utilise it in the 
measurement of FECH activity in the subjects of interest, a description of the 
assay, together with pertinent results and discussion on the optimisation 
thereof is included in the following sections. 
Materials and methods 
Following ethics approval (Appendix A), consenting subjects were provided 
with information regarding the study (Appendix B). Fifteen ml of heparinised 
blood was collected from 5 affected subjects - EPP8.1, EPP8.2, EPP8.4, 
EPP8.5 and EPP8.6. 
In addition, samples were obtained from 10 non-EPP controls (clinically 
and/or biochemically not affected by EPP).  
One subject known (identified by Parker et al 2008) to have clinical and 
biochemical EPP was included as a positive control.  This control subject 
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reported typical EPP-related photosensitivity and had a raised red cell PP of 
5160 nmol/L (normal < 2000 nmol/L). Additionally, EPP was confirmed by 
FECH genotyping (Parker et al 2008), which had shown the presence of the 
IVS3-48C polymorphism in intron 3 and a 757_761delAGAAG 5 base pair 
deletion in exon 7, which is a known EPP-associated mutation. 
EBVTL as an assay source of FECH 
B lymphocytes were transformed with EBV as described in Appendix E. EBV, 
though capable of infecting other cell types, has a specific tropism for B 
lymphocytes (Bird et al 1981). EBV particles were derived from the B95-8 
marmoset monkey cell line (Miller and Lipman 1973). In vitro, unchecked by 
an immune system, EBV drives EBVTL to proliferate by sustained expression 
of viral proteins (Thorley-Lawson 2001). 
It is interesting to reflect on the biology of in vitro EBV transformation. 
Following B lymphocyte infection via the cluster of differentiation (CD)21 
receptor (the viral ligand being glycoprotein 350) (Fingeroth et al 1984), EBV 
establishes a so called ‘latent’ infection. Viral DNA exists in episomal form 
within the nuclei of infected cells. Latency contrasts with lytic replication, 
which rarely occurs in human B lymphocytes in vitro. However, latency is a 
misleading term in so far as viral activity is concerned. Typically, all 9 viral 
‘latency’ proteins are expressed in EBVTL (Thorley-Lawson 2001).  
Latency proteins include the EBV nuclear antigen and latent membrane type. 
Examples of how EBVTL proliferation is stimulated include: 
– The resemblance of latent membrane protein 1 to a constitutively
active CD40 receptor, culminating in increased nuclear factor kappa
beta expression and EBVTL survival
– The ability of latent membrane protein 2 to mimic an intact B cell
receptor, so rescuing EBVTL from apoptosis
– EBV nuclear antigen 1 facilitated propagation of viral DNA to the
EBVTL progeny
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It was decided to use EBVTL (Figure 13) as a source of material for the 
following reasons: 
 
1. EBVTL, once established in culture, provide a renewable source of 
cells, allowing enzyme assays to be performed on multiple 
occasions. This was especially desirable during the initial phase of 
setting up the FECH assay. 
2. EBVTL also provide a renewable source of nucleic acids. DNA 
extracted directly from peripheral blood is stable and provides 
sufficient template for multiple assays. RNA, however, is unstable 
and large quantities are required per assay.    
3. EBVTL can be stored under liquid nitrogen for almost indefinite 
periods of time, allowing future studies to be undertaken. 
4. The use of EBVTL as a source of cellular material for measuring 
enzymes in the haem biosynthetic pathway has previously been 
validated (Meissner et al 1986, 1991) and EBVTL have been used 
to measure FECH activity (Gouya et al 2002, Risheg et al 2003).  
5. EBTVL culture is regularly performed in the Inherited Metabolic 
Disease laboratory (Division of Chemical Pathology, UCT and 
NHLS GSH) for routine diagnostic enzyme assays (i.e. other than 
FECH). 
6. The same quantity of lymphocytes required for a single FECH 
assay is used for lymphocyte transformation. Thus, for the same 
level of inconvenience to the blood-donating subject, increased 
utility is obtained. 
 
Two out of 5 EBVTL cell lines from affected members of family EPP8 were 
lost during culture due to unknown reasons. Possibilities include failure of the 
initial EBV infection to become established, bacterial infection, and 
excess/inadequate media. Repeat blood sampling was not possible. EBVTL 
cell lines from subjects EPP8.1, EPP8.2, EPP 8.5, 10 normal controls and 1 
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positive control were established. The fact that 2 cell lines were not 
established was considered acceptable, in the light of results obtained in the 
successful cell lines. 
After confirming cellular viability by phase contrast microscopy and the trypan 
blue exclusion test (Appendix E), EBVTL in culture medium were washed 
isotonically. This served to remove culture medium-derived protein and any 
impurities (with potential for fluorescence) which may be included in the 
medium. Sonication followed, solubilising the mitochondrial FECH (Appendix 
G). Sonicated protein concentration was determined by the Bradford method 
(Appendix F), and the samples were diluted appropriately to achieve 
comparable protein concentrations each time the assay was performed. 
Figure 13: EBVTL stained with Wright’s stain. 
The blasts are seen to have moderate amounts 
of deeply basophilic cytoplasm, folded to smooth 
nuclei, and multiple conspicuous nucleoli. On 
the left (100x mag), semi-confluent clumps and 
rosettes of cells are seen. Top left (1000x mag) 
shows an EBVTL resembling an immunoblast 
while a centroblastoid cell (1000x mag) with its 
progeny is seen above. 
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P = propionyl (CH2CH2COOH)
M = methyl (CH3)















FECH enzyme principle 
FECH activity was expressed as a rate as Zn meso (product) formation per h 
per mg of protein at 37 °C. The details of the FECH enzyme assay are 
described in Appendix G. Mesoporphyrin is a more suitable substrate to use 
than PP, because it is more soluble and stable than PP. In addition, 
mesoporphyrin has a lower Michaelis constant (KM) and a higher maximal 
FECH activity is recorded, compared to PP as substrate (Li et al 1987). The 














Figure 14: Mesoporhyrin dihydrochloride on the left and Zn meso on the right. 
The side groups represented by P, M and E are indicated. In the case of PP, 
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Figure 15: Under ultraviolet irradiation, mesoporphyrin (top, with magnetic stirrer) 
and Zn meso (bottom) fluoresce at an emission maxima of 620 nm and 577 nm, 
respectively. The more orange hue of the Zn meso fluorescence can only just be 
appreciated on this photograph. 
Zn chelation by mesoporphyrin, which occurs both enzymatically and non-
enzymaticallly, shifts the fluorescence emission maximum to a shorter 
wavelength (Figures 15 and 16) and the excitation maximum to a longer 
wavelength (Figure 17). Zn meso is thus readily distinguishable from its free 
form. Therefore, after termination of the reaction, Zn meso (present in nmol 
concentrations) may be measured at an excitation wavelength of 410 nm and 
an emission wavelength of 580 nm with relatively little interference from free 
mesoporphyrin (present in µmol concentrations) (Figure 18). 
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Zn meso (emission at 580 nm) and mesoporphyrin (emission at 
























Figure 17: Fluorescence is measured in a range of excitation wavelengths. 
The mesoporhyrin excitation maximum is at 393 nm and the Zn meso 
maximum at 408 nm (equimolar concentration of 500 nmol/L). Free 





Figure 16: Equimolar concentrations (500 nmol/L) of Zn meso and 
mesoporphyrin show peak fluorescence at 577 nm and 620 nm, 
respectively. Both compounds are excited at 410 nm, and the Zn meso 
fluoresces more intensely here than mesoporphyrin, because excitation is 
occurring at its excitation maximum. 
Zn meso and mesoporphyrin emission maxima on fluorescence 


























Figure 18: Comparison of emission spectra of 4 assay-relevant mixtures. Note 
how the blank fluorescence at 580 nm is composed of a small mesoporphyrin 
tail and some Zn meso formed by autochelation. The sonicated EBVTL sample 
was scanned after 1 h of incubation with substrate.The Zn meso standard 
contains 180 nmol/L Zn meso. 
After FECH is allowed to react with its substrates for 1 h during the enzyme 
assay, the fluorescence generated by a blank (with buffer replacing EBVTL 
sonicate), is subtracted from sample fluorescence. Enzymatic Zn meso 
formation is quantified using a Zn meso standard curve in which fluorescence 
is related to a known concentration of Zn meso. An emission wavelength of 
580 nm (rather than 577 nm) was chosen to maintain agreement with 
published methods (Li et al 1987, Rossi et al 1988, Gouya et al 2006). The 
blank and reaction fluorescence is compared to that of the mesoporphyrin 





































FECH assay variables and optimisation 
In order to ensure that the FECH assay was fully optimised and that maximal 
enzyme velocity was being measured, selected methodological variables 
were investigated.  
 
a) Method of cell lysis to solubilise FECH 
Whereas it is vital that FECH be released from mitochondria for assay, 
excessive sonication may thermally denature enzymes. Homogenisation is 
an alternative method of enzyme solubilisation, but is more tedious. Gouya et 
al (2006) used homogenisation while Rossi et al (1988) used sonication. 
Hence FECH activity was compared over varying sonication times (20 sec 
x1, 20 sec x2, 20 sec x3: in all cases at 3 watt), with homogenisation, and 
with sonication at 15 one sec bursts of 30% output. 
 
b) Comparison of FECH activity: lymphocytes and EBVTL 
In theory, EBVTL and peripheral lymphocytes may exhibit differing FECH 
activities. Using zinc and mesoporphyrin as substrates to measure FECH 
activity, Gouya et al (2002) showed similar results when using EBVTL and 
lymphocytes as tissue sources.  
However, as most authors (Rossi et al 1988, Gouya et al 2006) describe the 
use of lymphocytes to measure FECH activity, some form of comparison was 
necessary. EBVTL and peripheral lymphocytes from the same study subject 
were not available and could not be directly compared. However, peripheral 
lymphocytes were isolated (Appendix E) from 1 clinically normal subject and 
FECH activity was measured as an indication of lymphocyte FECH activity 
under our assay conditions. 
 
c) Accuracy of the Bradford protein assay 
The accuracy of the protein assay was assessed by measuring protein 
concentration in internal quality control material (U1 and U2 – Bio-Rad QC) 
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with assigned concentrations, using the Bradford method (Appendix F). This 
served to investigate the accuracy of the protein determination used in the 
determination of FECH activity over the concentration range experienced in 
our assay material. 
 
d) Palmitic acid activation of FECH 
The assay includes palmitic acid. Fatty acids (primarily palmitic acid) are 
known to activate FECH, which is useful in optimising assay conditions. The 
mechanism has not been elucidated but may involve the creation of a 
suitable micro-environment for catalytic activity. Taketani and Tokunaga 
(1981) hypothesise that it is due to the carboxyl groups of the palmitic acid 
which aid the approach of the porphyrin molecule to the catalytic site of 
FECH, perhaps by keeping porphyrins in solution. Addition of a detergent 
such as Triton X-100 is essential to dissolve palmitic acid. Varying palmitic 
acid concentrations in the final reaction mixture have been used: 0.70 
mmol/L - reported as optimal (Li et al 1987), 0.89 mmol/L – reported as 
optimal (Rossi et al 1988) and 0.76 mmol/L (Gouya et al 2006). Thus the 
FECH activity at varying palmitic acid concentrations was measured to 
determine optimal activity in our laboratory. 
 
e) Optimum pH used for FECH reaction 
An experiment was performed to compare a pH of 7.6 in the FECH enzyme 
assay as used by Gouya et al (2006) with the pH of 8 used by Rossi et al 
(1988).  
 
f) Volume of stopping solution used to terminate reaction 
The volume of dimethyl sulfoxide (DMSO) / methanol solution needed to 
terminate enzyme activity, and the need to transfer 1 ml of supernatant into 
the fluorimetry cell (Appendix G) were factors which prompted the 
determination of an optimum stopping solution volume. By adjusting volumes 
of Zn meso standard, sonication/incubation buffer and stopping solution, a 
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constant Zn meso concentration could be maintained while increasing the 
volume (and % volume contribution) of stopping solution to the final mixture 
which is transferred into the fluorimetry cell. 
g) FECH interassay variability
Reasonable reproducibility of EBVTL enzyme activity over time is essential 
for assay validity. However, fluxes in the growth and viability state of the 
EBVTL culture may occur and thus may influence activity. Hence, FECH 
activity from the same culture was assayed in 4 EBVTL cell lines over a 2 
month period in order to establish reproducibility. 
FECH assay of study subjects and controls 
After assay optimisation, EBVTL FECH activity was determined for 10 normal 
control subjects, 1 genotyped EPP positive control and 3 study subjects (see 
“FECH enzyme principle” above and Appendix G). 
Data analysis 
FECH activity measurements (Table 7) were performed in triplicate to 
increase the precision of the results and the mean calculated. 
Data generated were plotted, and graphs constructed using Microsoft Excel. 
Statistical comparison of FECH enzyme data of 10 normal controls and 3 
study subjects from the family EPP8 was conducted using Statsoft Statistica. 
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Results 
FECH assay variables and optimisation 
 
a&b) Homogenisation vs sonication yields comparable results, but as higher 
activities are obtained with shorter periods of sonication time, it is important 
to minimise rather than maximise the sonication period. Activity for 
lympocytes is similar to that of EBVTL (Table 5). 
 
c) Protein measurement of internal quality control material by the Bradford 
method showed values within 2 SD of the assigned mean – and thus 
considered acceptable (Table 6). 




protein at 37°C) 
Comparison of homogenisation and sonication 
Control 4 Homogenisation 1.07 
Control 4 Sonication 3W x20 sec x3 1.10 
Comparison of sonication time 
EPP8.2 Sonication 3W x20 sec x1 1.37 
EPP8.2 Sonication 3W x20 sec x2 1.20 
EPP8.2 Sonication 3W x20 sec x3 1.21 
EPP8.2 
Sonication 15 one sec bursts 
of 30 % output 
1.40 
Lymphocytes as tissue medium 
Control 
Lymphocytes  
Routine assay (Appendix G) 1.32 
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Figure 19:  FECH activity as a function of varying palmitic acid concentration. 
(Data points obtained from a single experiment). EBVTL from control 6 has 
been used as a source of FECH. 
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d) FECH activity in a range of palmitic acid concentrations shows optimum 
activation at 0.76 mmol/L (Figure 19). 
 
e) A pH of 7.6 was considered optimum for FECH, based on the typical pH 
ranges reported (Rossi et al 1988, Gouya et al 2006).  No difference in 
activity over a pH 7.6 – 8.0 range was noted (data not shown). 
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f) An experiment to determine variation of fluorescence as a function of the % 
volume contributed to the final assay mixture by the stopping solution, 
showed an 8% variation, with no particular trend. This was considered within 
experimental error. A range of stopping solution volumes could be used, but 
1000 µl was established as the most convenient. 
 
g) Assay reproducibility was assessed on at least 3 occasions during a 2 
month time period in 4 EBVTL cell lines (2 controls, 2 subjects) and found to 
be reproducible with a coefficient of variation of 12% (data not shown). 
 
The final optimised assay conditions which were employed (Appendix G) in 
order to establish FECH activity in family EPP8 were similar to that used by 
Gouya et al (2006) – the only distinct difference being that sonicated EBVTL 




Experimental FECH results 
FECH enzyme activities in normal controls, the genotyped EPP positive 
control and affected subjects from family EPP8 are shown in Table 7. No 
significant differences between FECH activities in the normal controls and in 
members of family EPP8 are apparent. 
Table 7: FECH activity in controls and family EPP8 subjects 
Sample FECH activity (nmol/h/mg protein at 37°C) 
Normal control 1 1.14 
Normal control 2 1.34 
Normal control 3 1.26 
Normal control 4  1.14 
Normal control 5 1.24 
Normal control 6 1.11 
Normal control 7 1.23 
Normal control 8 1.09 
Normal control 9 1.58 
Normal control 10 1.38 
 
Normal control mean ± standard deviation = 1.25 ± 0.15 (nmol/h/mg protein at 37 ° C) 
 
Genotyped positive EPP 







The FECH activity assay, (Gouya et al 2006), was suitable for measuring 
FECH activity from EBVTL. The assay required very little modification, was 
optimised as described above and was capable of detecting significant 
aberrations in FECH activity from lymphocyte-derived material. 
The mean normal FECH activities previously reported were 3.25 (Rossi et al 
1988) and 4.83 (Gouya et al 2006) nmol/h/mg protein at 37 °C, respectively. 
This corresponded to a 2.6 and 3.9 fold higher mean FECH activity 
measurement than that recorded here (1.25 nmol/h/mg protein at 37 °C). A 
significant interlaboratory bias, which ultimately could not be explained, was 
present. However, the use of a standard curve to quantify Zn meso 
concentration suggests that general ‘laboratory’ variation such as 
instrumentation used, was not causative. Similarly, although Zn meso 
fluorescence was measured at an emission wavelength of 580 nm and not at 
its peak (577 nm), standard and sample fluorescence should be affected 
equally, resulting in accurate measurement. The FECH assay was fully 
optimised, true maximal FECH velocity was being measured, and protein 
measurement was accurate and representative of functional FECH.   
One positive EPP control was investigated in order to validate the assay as a 
means with which to diagnose FECH-deficient EPP. This positive control was 
known to carry the FECH IVS3-48C polymorphism and 757_761delAGAAG 
mutation. FECH activity was significantly decreased compared to the normal 
control group (18%, expressed as a percentage of the normal mean). This is 
consistent with the 10 – 30% range for FECH activity in autosomal dominant 
EPP (Gouya et al 2006). Based on this result we were satisfied that the 
assay was capable of functioning as a diagnostic tool. Due to time-
constraints and the lack of easily available tissue, it was not considered 
necessary to add further EPP patients to a positive control cohort. 
Importantly, subjects EPP8.1, EPP8.2 and EPP8.5 did not have significantly 
different FECH activities when compared to the control group (p = 0.735, 
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Mann-Whitney U-test). Thus, it was apparent that a reduction in FECH 
activity was not the likely primary cause of the porphyria in these patients. 
This is consistent with the other atypical findings discussed in Chapters 2 and 
3. These findings, together with those of Parker et al (2008) in which no DNA 
variant in the FECH gene was noted in this family, were strongly suggestive 





1. A FECH enzyme activity assay was successfully established in our 
laboratory. It was reproducible, optimal and was capable of distinguishing 
between normal and FECH-deficient EPP subjects. The assay may thus 
be used to aid in the diagnosis or exclusion of EPP.  
2. Three subjects from family EPP8, with clinical and biochemical evidence 
of protoporphyria, were found to have FECH activity within the normal 
range. 
3. This result supports the suggestion that the disease locus in family EPP8 











As set out in the section entitled ‘Additional aims and objectives’ (Chapter 2), 
in the light of no apparent FECH involvement in the disease, the objective 
was redirected to search for non-FECH genes/loci/disease mechanisms in 
order to explain the protoporphryria observed in family EPP8. 
In Chapter 2 we indicated that international collaboration had been 
established in 2007 with researchers in Wales (University of Cardiff) and 
France (Centre Francais des Porphyries). They had noted and investigated 
atypical EPP patients with a porphyric syndrome very similar, if not identical, 
to those found in family EPP8. 
At the time of conducting FECH activity measurements which the previous 
chapter has detailed, a seminal discovery was made – an alternative 
disease-causing locus was identified. Mutations in the erythroid specific 5-
aminolevulinate synthase (ALAS2) gene were present in affected members 
of family EPP8 and 7 other families abroad and resulted in a gain of function 
in ALAS2 (Whatley et al 2008). 
The realisation that a mutation in the first enzyme in the haem biosynthetic 
pathway was porphyria-causing, brought about a paradigm shift in the 
investigations described in the remainder of this dissertation; allowing the 
additional aims and objectives outlined in Chapter 2, to be developed. 
With the alternative disease locus identified, and with the lack of evidence for 
FECH mutations (Parker et al 2008) or FECH enzyme dysfunction in family 
EPP8 (see above), it was decided unnecessary to further investigate FECH 
at RNA or protein level.  
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ALAS2 and X-linked dominant 
protoporphyria 
 
In the international collaboration 8 families exhibiting features of an atypical 
protoporphyria syndrome were identified – this included our family EPP8 
(Whatley et al 2008). Examination of family pedigrees revealed an X-linked 
inheritance pattern. Using a candidate gene approach, 2 disease-causing 
frameshift mutations in ALAS2 exon 11 were found: coding sequence 
(c.)1706-1709 delAGTG in family EPP8 and 5 other families; and c.1699-
1700 delAT in 2 families. Expression of the ALAS2 mutations in a prokaryotic 
system showed that both ALAS2 activity and porphyrin synthesis were 
markedly increased. The atypical protoporphyria syndrome resulting from a 
gain of function mutation in ALAS2, was named X-linked dominant 
protoporphyria (XLDPP). The dominant inheritance pattern and almost 100% 
penetrance observed, was caused by this gain in ALAS2 function. 
Although mutational analysis of ALAS2 exon 11 in family EPP8 was 
performed by Whatley et al (2008), samples from subjects EPP8.3, EPP 8.10 
and EPP 8.11 had not been available at that study. The need to offer DNA 
based diagnoses to these 3 subjects, and any other patients who might 
warrant investigation for XLDPP, prompted us to establish a method for 
ALAS2 exon 11 mutational analysis in our laboratory. 
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The ALAS2 gene 
 
The reaction catalysed by ALAS2, its regulation in erythroid tissue, and the 
importance thereof in establishing flux through the haem biosynthetic 
pathway, have been detailed in Chapter 1.   
The human ALAS2 gene is ~ 23 000 base pairs (bp) in size (Ensembl Human 
Geneview) and a diagram depicting its organisation is presented in Figure 
20. The coding sequence consists of 1761 bp for 587 amino acids. The 
ALAS2 promoter includes GATA-1 and EKLF binding sites. Intronic enhancer 
sequences with the ability to bind GATA-1 are found in introns 1 and 8 
(Sadlon et al 1999).  
Exon 2, the first coding exon, contains the mitochondrial signal sequence 
which is cleaved during translocation into the mitochondrial matrix. 
Alternative splicing causes the exclusion of exon 4 to yield an mRNA isoform 
which constitutes ~ 40% of total ALAS2 mRNA. This isoform produces a 
functional enzyme, with mildly reduced catalytic activity. Other minor isoforms 
are also described, yielding truncated and probably non-functional ALAS2 
(Cox et al 2003). 
Mutations in ALAS2 are numbered and named using the coding sequence 
numbers, commencing with the ATG start codon in exon 2. ALAS2 exons 5 - 
10 encode the catalytic domain and numerous loss of function mutations 
have been reported, resulting in XLSA (Sadlon et al 1999). Earlier work has 
suggested that the catalytic domain would include exon 11 (Cox et al 1991, 
Sadlon et al 1999, Cox et al 2004), but this could not be proved by 
crystallography. The only crystal structure available for ALAS (Astner et al 
2005) is a bacterial (Rhodobacter capsulatus) ALAS which does not include 
exon 11. Intriguingly, a loss of function missense mutation in exon 11 
(S568G), in very close proximity to the 2 gain of function XLDPP mutations, 
has been reported (Harigae at al 1999). In the light of the exon 11 mutations 
described in XLDPP, the suggestion is that the C-terminus appears, in some 
way, to modulate enzyme activity (Whatley et al 2008).  
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Figure 20: Human ALAS2 gene organisation showing the promoter, containing binding 
sites for erythroid transcription factors (GATA, EKLF). An iron response element (IRE) 
is located in the 5’ UTR. Also shown are 11 exons, 10 introns, other relevant 
sequences (discussed in text) and mutations causing XLSA in exons 5 – 11 (adapted 
from Sadlon et al 1999). Mutations in exon 11 causing XLDPP are indicated. Question 
marks refer to postulated catalytic modulation by the C-terminal domain located in exon 














Materials and Methods 
 
DNA was extracted from EDTA blood samples (Appendix H). Subjects 
EPP8.8 and EPP8.7 (non-related spouses of affected family members) were 
included as family controls and used as wild type (WT) DNA. 
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The genomic ALAS2 sequence was accessed on Ensembl Human 
Geneview: Ensembl number 00000330807; sequence = ALAS2-006 
(http://www.ensembl.org). 
The mRNA ALAS2 sequence was accessed on Genbank: Accession number 
NM000032.4; non splice variant sequence = isoform a 
(http://www.ncbi.nlm.nih.gov). 
A 417 bp fragment from exon 11 was chosen for amplification by PCR 
(Appendix J) to enable inspection of the entire exon and flanking introns. 
Figure 21 illustrates the ALAS2 exon 11 region, relevant mutations and 











Figure 21: ALAS2 exon 11 WT sequence (upper case) and flanking introns (lower 
case). The numbered exon 11 sequence commences with the boxed A base 
(c.1601). Complementary intronic sequences to forward and reverse primers for the 
417bp fragment amplification are underlined and in blue. The 4 bp AGTG deletion 
relevant to family EPP8 is indicated in red and boxed. The other XLDPP causing AT 
deletion is doubly underlined and indicated in red. The S568G mutation in codon 
568 (AGT) is dotted and causes XLSA (Harigae et al 1999). The ALAS2 WT stop 
codon (TGA) is indicated in green and underlined; preceded by the final coding C 
base (boxed, c.1761). The alternative distal stop codon (TAG) created by the 
c.1706-1709 delAGTG mutation is shown in green. The premature stop codon
(TGA) created by the c.1699-1700 delAT mutation is indicated in pink - located
immediately before and shares the first base of the boxed AGTG region.
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Primer sequences used for the PCR were as follows (design discussed in 
Appendix I): 
• Forward: 5’ – ctt ggc tca tct gta ctg tg – 3’ 
• Reverse: 5’ – gga gtc aga atg cac ttg tc – 3’ 
A temperature gradient PCR (discussed in Appendix I) was run to determine 
the optimal annealing temperature empirically. 
Polyacrylamide gel electrophoresis (PAGE) was used to confirm amplification 
of the desired 417bp fragment (Appendix K). Whilst agarose gel 
electrophoresis would be an easier alternative to PAGE to be used as a 
checking gel, we elected to use PAGE because of personal and laboratory 
preference. 
Direct sequencing of the 417 bp fragment was used to identify any sequence 
variation. Restriction digestion based analysis was not performed because 
the c.1706-1709 delAGTG mutation does not create or abolish a restriction 
site (as verified with NEBcutter V2.0, New England Biolabs, 
http://tools.neb.com/NEBcutter2/index.php). Prior to sequencing, amplicons 
were purified (Appendix L) and prepared as per the requirements of the 




Figure 22 shows PAGE of a temperature gradient PCR. An annealing 
temperature of 52 °C was selected. Amplification and PAGE of DNA from 
family EPP8 is shown in Figure 23. Heteroduplexes were observed in 
affected female subjects. 
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Figure 22: PAGE (6%) of gradient PCR, ALAS2 exon 11 using control DNA. Non-
specific product formation ~ 150bp in size is seen in lanes 5 – 8. Optimum amplicon 
formation was identified in lane 3. 
 
Lane 1: 56 °C  
Lane 2: 54 °C  
Lane 3: 52 °C  
Lane 4: 50 °C  
Lane 5: 48 °C  
Lane 6: 46 °C  
Lane 7: 44 °C 
Lane 8: 42 °C 
Lane 9: Blank 
Lane 10: 100bp DNA ladder 
400 bp 
300 bp 
 500 bp 
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Figure 23: PAGE (6%) confirms amplification of the 417 bp product from members 
of family EPP8 and controls. Two different heteroduplexes migrating at ~700 /780 
bp positions are seen in lanes 3, 5 and 7. Separation of 2 bands migrating at ~ 415 
bp can only just be visualised in lane 7.  
 
Lane 1: Blank 
Lane 2: Subject EPP8.2 (affected male) 
Lane 3: Subject EPP8.6 (affected female) 
Lane 4: Subject EPP8.7 (family control, male) 
Lane 5: Subject EPP8.5 (affected female) 
Lane 6: Subject EPP8.9 (unaffected male) 
Lane 7: Subject EPP8.1 (affected female) 
Lane 8: Subject EPP8.8 (family control, female) 







Figures 24 – 26 shows partial sequencing results from a family control and 
subjects affected by the c.1706-1709 delAGTG mutation. The results of 
ALAS2 exon 11 mutational analysis of family EPP8 correlated with 







Figure 24: Partial direct sequence of WT ALAS2 exon 11 using forward primer.  The 











       















Figure 25: Partial direct sequence of c.1706-1709 delAGTG ALAS2 exon 11 using 
forward primer in subject EPP8.2 (affected male).  The WT sequence is shown 
above the mutant for comparison. 
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Figure26: Partial direct sequence of c.1706-1709 delAGTG ALAS2 exon 11 using 
forward primer in subject EPP8.5 (affected female).The WT sequence is shown 
above the mutant for comparison. 
 
 
Table 8: ALAS2 exon 11 mutational analysis results 
Subject 
Protoporphyric 
phenotype Mutational Status 
EPP8.1 Affected c.1706-1709 delAGTG 
EPP8.2 Affected c.1706-1709 delAGTG 
EPP8.3 Unaffected WT 
EPP8.4 Affected c.1706-1709 delAGTG 
EPP8.5 Affected c.1706-1709 delAGTG 
EPP8.6 Affected c.1706-1709 delAGTG 
EPP8.7 Family control WT 
EPP8.8 Family control WT 
EPP8.9 Unaffected WT 
EPP8.10 Unaffected WT 
EPP8.11 Unaffected WT 
EPP8.12 Affected 
EPP8.13 Asymptomatic 




Exon 11 PCR analysis of the ALAS2 gene was successfully performed as 
described.  
Five family members had the c.1706-1709 delAGTG mutation, all of whom 
were clinically and biochemically affected. The molecular result was 
diagnostically useful, and allowed clinicians to understand and rationalise the 
disease better. This had significant implications for family EPP8, permitting 
clinical dialogue with family members. Issues discussed included the c.1706-
1709 delAGTG mutation, postulated pathogenesis, mode of inheritance and 
assessment of genetic risk to future generations (Appendix N). 
In subjects carrying the c.1706-1709 delAGTG mutation, interesting 
differences between male and female PAGE and sequencing results were 
seen. Males are hemizygous for genes on the X chromosome, while females 
may be homozygous or heterozygous. Thus, in the presence of a mutation 
on the X chromosome, heteroduplexes (on PAGE) and overlapping ddNTP 
signals (sequencing) is only seen in females. Heteroduplexes (Figure 23) are 
seen as 2 different bands, interpreted as 2 different double stranded DNA 
structures - sense and antisense WT, hybridised with its complementary 
delAGTG strand. 
Furthermore, in heterozygous females, the 417 bp and 413 bp fragments can 
be seen as separate bands when resolution was improved by loading less 
DNA (Figure 23, lane 7). Other strategies may also be employed to improve 
resolution between fragments of differing size on PAGE (discussed in 
Appendix K), such as redesigning the PCR to generate a shorter fragment. In 
such manner detection of the c.1706-1709 delAGTG mutation without the 
need for sequencing may be possible, even in males – similar to the 
commonly employed amplicon size discriminatory technique used as a 
diagnostic method  for the ∆F508 cystic fibrosis mutation. However, because 
the region of interest contains at least 3 different mutations in very close 
proximity, the utility of sequencing would remain. 
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ALAS2 exon 11 mutational analysis of family EPP8 was in keeping with their 
phenotypic presentation. That is, we only observed clinical and biochemical 
evidence of protoporphyria in mutation-positive subjects (Table 8). Although 
not normalised for factors such as iron status, it was interesting to note that 
the red cell PP determinations obtained at the time of this investigation 
(Table 3 in Chapter 3) seemed to indicate that the highest concentrations 
correlated with the most severe reported skin disease. 
The c.1706-1709 delAGTG mutation is predicted to cause a frame shift in 24 
codons distal to the 4 bp mutation (p.E569GfsX24), resulting in the extension 
of ALAS2 by 4 amino acids. In contrast, the c. 1699-1700 delAT mutation 
leads to a frameshift mutation in 2 codons (p.M567EfsX2) and a truncation of 
ALAS2 (Whatley et al 2008). It is interesting that a single bp substitution in 
this same region (S568G) reportedly causes a loss of function in ALAS2, 
manifesting as XLSA (Harigae et al 1999). This mutation is located between 
the 2 XLDPP-causing mutations, as depicted in Figure 21. It is surprising that 
mutations in such close proximity, can have diametrically opposite effects. 
The exact mechanism by which the XLDPP mutations increase ALAS2 
activity, has not been determined. Iron as substrate has been postulated to 
become rate-limiting, leading to PP accumulation (Whatley et al 2008). This 





1. This study confirmed the presence of the c.1706-1709 delAGTG 
mutation in family EPP8. Furthermore, additional subjects not 
available to the initial published investigation (Whatley et al 2008) 
confirmed the mutation to be disease-associated. 
2. DNA based detection of c.1706-1709 delAGTG was extremely useful 
in the investigation of porphyria in subjects from family EPP8 and 
allowed better understanding of the disease, with concomitant benefit 














Better knowledge of the molecular pathogenesis in XLDPP allowed the 
investigation of potential treatment in the form of iron supplementation, and is 
described here. Hence, this section of the study was aimed at exploring the 
effect of iron supplementation on PP metabolism and thereby assisting our 
understanding of the condition. The data are presented with the kind 
permission of the clinician responsible for the care of subject EPP8.2, Dr M 
Sonderup (Department of Medicine, UCT and GSH) (Sonderup et al 2009). 
Introduction 
 
Bone marrow biopsy (November 2007, Chapter 3) of patient EPP8.2, showed 
decreased iron stores. Serum iron biochemistry (December 2007, at initial 
GSH evaluation, Chapter 3) was difficult to interpret in view of an acute 
phase response and hepatic damage, but was suggestive of iron deficiency. 
There was no obvious recent cause of iron loss (e.g. haemorrhage), iron 
supplementation or blood transfusion preceding this documentation of iron 
deficiency. 
It was postulated that in XLDPP iron availability becomes rate limiting for 
FECH activity because of increased flux of the haem biosynthetic pathway 
due to increased ALAS2 activity (Whatley et al 2008). In light of evolving 
information which became available at the time of the discovery of the ALAS2 
mutations, it was considered mandatory to ensure that subject EPP8.2 was 
iron replete.  
Prior to the intravenous iron replacement discussed in this chapter, iron 
stores were supplemented by way of blood transfusions in April 2008. This 
was necessary because of haemorrhage related to a gall bladder/liver fine 
needle aspirate biopsy in the context of portal hypertension. Sepsis and the 
anaemia of chronic disorders may have contributed to the anaemia.  
Anaemia or iron overload have not been associated with the syndrome of 
XLDPP, apart from a single patient who developed iron deficiency anaemia 
as a consequence of bleeding from a gastric ulcer (Whatley et al 2008). In 
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that patient, a decline (though not a normalisation) in red cell free PP 
concentrations paralleled treatment and resolution of iron deficiency anaemia 
with oral iron supplementation. 
Although the mean haemoglobin concentration and red cell volume was 
normal in XLDPP patients, iron studies were in keeping with iron deficiency - 
particularly in male subjects (Whatley et al 2008). Mean serum ferritin and 
transferrin saturation were decreased, while soluble transferrin receptor 
concentration was increased. These results were significant (p < 0.05) when 
compared to those obtained from unaffected relatives. Similar serum iron 
parameters have been recorded in subjects from family EPP8, e.g. subject 
EPP8.4 (Table 4). As stated in Chapter 3, the ability of intravenous iron to 
decrease photosensitivity temporarily (sustained subjective symptom relief 
for up to 4 months in subject EPP8.6, and 1 year in subject EPP8.1), was 
noted by affected subjects from family EPP8. This was confirmed by treating 
clinicians. Interestingly, patients insisted that oral iron treatment did not 
achieve an effect similar to that of the intravenous form. Indeed, before 
knowledge of the c.1706-1709 delAGTG mutations in ALAS2 was available, 
response to iron constituted one of the atypical features in family EPP8. Iron 
treatment described here was part of the overall and complex management 
of patient EPP8.2, as described in Chapter 3. 
Method 
Two hundred mg elemental iron was infused intravenously on 4 occasions 
into patient EPP8.2. The first 3 of these infusions were clustered together 
over a period of 5 days at the end of May to the beginning of June 2008. 
Serum iron biochemistry (using routine automated methods) and red cell PP 
concentrations (Appendix C) were measured over the ensuing 2 months to 
assess response.  
Intravenous iron was in the form of Venofer, an iron sucrose complex with a 
MW of 34 000 – 60 000. This complex is taken up by the reticuloendothelial 
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system (RES) and dissociated into iron and sucrose, resulting in a relatively 




Data generated during iron treatment of patient EPP8.2 are displayed in the 
following series of figures (Figures 27 – 31). 
Figure 27 documents the rapid increase in serum iron concentrations 
following iron administration. Figure 28 shows a modest reduction in serum 
transferrin concentrations. This results in a marked increase in serum 
transferrin saturation with iron treatment, as seen in Figure 29. The increase 
in iron stores is reflected in the increase in serum ferritin (Figure 30). 
Red cell PP response during iron treatment is presented in Figure 31. After 
an initial dramatic increase, PP concentrations decrease during iron 
treatment, but do not reach the reference interval.  
 
 








 Figure 27: Effect of parenteral iron treatment (red arrows) on serum iron 
concentration over time. Data courtesy of Dr M Sonderup (Department of 
Medicine, UCT and GSH). Upper and lower limit of reference intervals are shown 





Figure 28: Effect of parenteral iron treatment (red arrows) on serum transferrin 
concentration over time. Serum transferrin concentration remains low, in 
keeping with a negative acute phase response, during iron treatment. Data 
courtesy of Dr M Sonderup (Department of Medicine, UCT and GSH). Lower 
limit of reference interval shown as green stippled line. 
Figure 29: Effect of parenteral iron treatment (red arrows) on % serum 
transferrin  saturation over time. Serum transferrin saturation increases during 
iron treatment. Data courtesy of Dr M Sonderup (Department of Medicine, UCT 





















































Figure 30: Effect of parenteral iron treatment (red arrows) on serum ferritin 
concentration over time. Serum ferritin concentration increases during iron 
treatment. Data courtesy of Dr M Sonderup (Department of Medicine, UCT and 
GSH). Upper and lower limits of reference intervals shown as green stippled lines. 
Figure 31: Effect of parenteral iron treatment (red arrows) on red cell PP 
concentration over time. PP increases dramatically, and then decreases, during 
iron treatment. Data courtesy of Dr M Sonderup (Department of Medicine, UCT 




The observation that iron treatment increases, and then decreases serum PP 
concentrations, was somewhat surprising. Importantly, this flux in PP was 
recorded in a state of probable iron deficiency.  
In XLDPP (even in the absence of iron deficiency), if iron delivery to FECH 
within the mitochondrion was insufficient to match PP production, iron 
supplementation would constitute a rational treatment strategy by decreasing 
PP accumulation.  
It may be postulated that the initial rise in red cell PP was a consequence of 
increased ALAS2 translation due to signalling though the IRP system. 
Increased normoblast cytosolic iron would decrease IRP 1 and 2 levels, 
leading to ALAS2 mRNA stabilisation. This effect would occur in a state of 
iron deficiency, in keeping with the observations of Ishikawa et al (2005), and 
account for the relatively brief period of ALAS2 induction. It may be that the 
initial increase in red cell PP described here, would not be seen if subject 
EPP8.2 had been systemically iron replete. 
Iron treatment may decrease PP concentrations in XLDPP by allowing 
accumulated PP to be metabolised to haem, due to the restoration of 
matching iron and PP substrate proportions. Increased iron concentrations, 
capable of saturating FECH activity, would achieve this effect in XLDPP even 
in the absence of systemic iron deficiency.  
Another mechanism by which iron treatment may decrease PP 
concentrations in XLDPP, and specifically during iron deficiency, would be a 
reduction in ALAS2 transcription, as a consequence of restoration of normal 
haemoglobin oxygen carrying capability. Anaemia due to any cause, acting 
through erythroid transcription factors, may be expected to increase ALAS2 
transcription (Nuez et al 1995, Marinkovic et al 2007), but in general XLDPP 
subjects do not exhibit anaemia (Whatley et al 2008). However, in the case of 
subject EPP8.2, anaemia was present (Hb = 10.9g/dl) when iron treatment 
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was given - although the origin of this was, as previously mentioned, 
probably a result of haemorrhage, sepsis and the anaemia of chronic 
disorders. Subjects EPP8.6 and EPP8.4 reportedly had associated anaemic 
episodes (haemoglobin of 8 and 10 g/dl, respectively) with their porphyria, 
but an unrelated factor (e.g. heavy menses) cannot be excluded. The 
increased photosensitivity they describe whilst anaemic, and the resolution of 
the anaemia and photosensitivity with intravenous iron treatment, does not 
establish XLDPP as the basis for the anaemia. 
Iron and ferritin concentrations remain elevated for ~ 3 weeks after the iron 
infusions (Figures 27 and 30) in subject EPP8.2. Intravenous iron is taken up 
directly by the bone marrow reticuloendothelial system (RES) and stored as 
ferritin, in contrast to oral iron supplementation, which is siphoned off by the 
liver before entering the systemic circulation. Macrophage “nurse cells” 
frequently exist in proximity to normoblasts, supplying them directly with iron 
(Leimberg et al 2008). Potentially, iron concentrations remain elevated within 
the bone marrow micro environment for longer than serum iron studies would 
indicate. Thus, supra-physiological iron concentrations achieved during iron 
treatment would be expected to increase the total RES iron delivery 
capability.  
Serum transferrin concentrations show a reduction after iron treatment 
(Figure 28), interpreted as a hepatic response to increased serum iron 
concentrations. Note that the transferrin concentration prior to iron treatment 
was borderline low, possibly secondary to hepatic disease and as an acute 
phase response. As another possible confounding factor, it is interesting to 
note that Lyoumi et al (2007), using a murine model, showed an increase in 
serum transferrin as a direct result of raised PP concentrations.  
Increased flux of the haem biosynthetic pathway in XLDPP, suggests an 
increase in haem formation. The fate of this haem has not been determined 
(Whatley et al 2008), but deserves consideration. Normally, erythroid haem 
may be incorporated into haemoglobin, possibly exported from normoblast as 
free haem by the feline leukemia virus subgroup C receptor (FLVCR) (Keel et 
al 2008), or be broken down within the normoblast by haem oxygenase. 
Breakdown of haem yields inorganic iron, carbon monoxide and biliverdin. 
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Free haem is bound to haemopexin in plasma. The haem-haemopexin 
complex is taken up by the low density lipoprotein receptor related protein 
(LRP) in the bone marrow and spleen RES (Hvidberg et al 2005). The LRP, 
also known as CD91, is more well-known for its role as receptor for 
lipoproteins. In a very similar system, free haemoglobin bound to haptoglobin 
can be taken by the CD163 receptor. In both cases haem is targeted for 
lysosomal degradation. These receptors are also expressed in other tissues, 
such as liver (Hvidberg et al 2005). The RES may also acquire haem by 
phagocytosis of senescent or abnormal red cells. Inorganic iron may be 
exported from macrophages via ferroportin. Intact haem may also leave 
macrophages via the FLVCR (Keel et al 2008).  
In all cases, this system achieves recycling and conservation of iron stores. 
In view of this, it is perplexing that in XLDPP increased flux of the haem 
biosynthetic pathway results in failure of mitochondrial iron availability. 
In XLDPP, biochemical iron parameters may be in keeping with iron 
deficiency although total body iron stores may be normal (arbitrarily called 
postulate A here). This would be expected to occur if an increased flux of the 
haem biosynthetic pathway led to increased erythron iron acquisition, haem 
synthesis and eventually catabolism by the RES. The rate-limiting step, 
leading to PP accumulation, could then be postulated as being RES 
processing or release of recycled iron for erythron uptake. Disorders in which 
RES iron release is decreased, such as the anaemia of chronic disorders 
(increased hepcidin causing ferroportin transporter degradation) or scurvy, 
would be expected to reduce RES iron release even further.   
As mentioned in Chapter 1, excess haem has been shown to impair erythron 
iron uptake (Ponka and Schulman 1985). In these in vitro experiments 
exogenous haem was added to incubated reticulocytes. Excess haem 
production is expected to occur in XLDPP, and this haem may impair 
erythron iron acquisition. However, it may be that the haem concentrations 
achieved in the experiments of Ponka and Schulman, and those which occur 
in XLDPP, are of different orders of magnitude. Furthermore, endogenous 
haem in excess of globin requirements may be exported by the FLVCR, 
thereby preventing intracellular haem toxicity (Keel et al 2008). Although 
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haem is known to degrade IRP2 via oxidation-induced ubiquitination 
(Ishikawa at al 2005), and such reduction in IRP2 may impair erythroid 
transferrin receptor expression in response to intracellular iron deficiency, the 
effect of this system in XLDPP has not been determined. Decreased serum 
transferrin saturation prior to iron treatment (Table 4 and Figure 29) and 
increased soluble transferrin receptor concentrations (Whatley et al 2008, but 
not measured in family EPP8) suggest increased, although insufficient, 
uptake of available iron by erythroid cells. It is possible that the effect of 
increased haem (if indeed present in XLDPP) on normoblast IRP2 signalling 
and consequent transferrin receptor expression, is overshadowed by other 
mechanisms.  
If XLDPP does not cause systemic iron deficiency, ongoing iron treatment 
would entail a risk of systemic iron overload with associated toxicity. This 
would imply that PP reduction after iron treatment is simply a non-steady 
state phenomenon and that eventually iron would be incarcerated in the 
RES. 
If XLDPP does cause total body iron deficiency (arbitrarily called postulate B 
here) – and biochemical parameters do in fact reveal systemic iron deficiency 
- on-going iron treatment may be partially curative. Keel et al (2008) postulate 
that free haem may be secreted by the liver into bile via the FLVCR, and thus 
provide a route of net iron loss from the body. This would provide an 
explanation for the reduction in iron stores observed in patient EPP8.2 at 
initial evaluation, for which no clear aetiology has been advanced.   
Although it is tempting to hypothesise that haem production is stimulated in 
XLDPP through iron administration, it is prudent to remain speculative on this 
issue, and likewise on the role that the above mechanisms may be playing. 
Indeed, the disposal or use of iron after haem synthesis in XLDPP has not 
been determined (Whatley et al 2008). Pending further investigation, a 
reasonable compromise between postulate A and B explaining inadequate 
mitochondrial iron availability, is to conclude that some measure of increase 
in total body iron stores would be required to match increased PP production 
and compensate for any iron loss sustained. This would imply a restoration of 
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normal iron and PP proportions, albeit at increased concentrations, perhaps 
by raising actual in vivo FECH activity and PP clearance. 
Conclusion 
1. Iron supplementation does appear to alter porphyrin metabolism in
XLDPP as evidenced by an initial increase in erythocyte PP
concentration, followed by a more sustained decrease, after iron
treatment.
2. Iron treatment of subject EPP8.2, though reducing PP concentrations
temporarily, did not reverse the inexorable advance of an established liver
disease process.
3. It is difficult to quantify the impact iron treatment had on the course of his
disease. Multiple confounding variables caused by advanced liver
disease, means that the findings discussed here cannot necessarily be
extrapolated to other subjects with XLDPP.







Further discussion and 






“…..who are first will be last, and the last - first.” 
     Matthew 19: 30, Bible International Version 
 
 
It is ironic that a mutation in the first enzyme in the haem biosynthetic 
pathway results in dysfunction and substrate accumulation at the level of the 
last. The discovery of ALAS2 as the disease locus in family EPP8 explains 
many of the perplexing and atypical features initially noted by Parker et al 
(2008) and our collaborators at the University of Cardiff and the Centre 
Francais des Porphyries. However, a variety of new and as yet unanswered 
questions emerge. The following discussion points are made on the basis of 
a more comprehensive view and understanding of family EPP8 as work 
progressed.  
 
Features of XLDPP and Family EPP8 
 
The preponderance of ZnPP in family EPP8 and XLDPP is understood to 
reflect a state of relative mitochondrial iron deficiency – zinc being used by 
FECH as an alternative to iron. It is interesting that during the final phase of 
his illness, subject EPP8.2 reverted to a dominant free PP peak. This may 
reflect exhaustion of zinc as alternative FECH substrate. Zinc deficiency may 
be predominantly within normoblasts due to significantly increased flux of the 
haem biosynthetic pathway, but serum zinc deficiency as associated with 
catabolic states may have been contributory (unfortunately serum zinc levels 
were not measured). Whatley et al (2008) noted a similar pattern in the 
XLDPP patient they described who had iron deficiency (ZnPP plateaued 
while free PP increased significantly). 
While G6PD deficiency was not confirmed in our study it is interesting to note 
that such deficiency may have been of clinical relevance in the affected male 
subjects from family EPP8. Particularly during the final phase of his illness, 
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PP accumulation and sepsis in subject EPP8.2 may have created sufficient 
oxidant stress to have generated haemolysis. However, no clear 
morphological evidence of haemolysis was found on examination of 
peripheral blood at that time. Other parameters such as unconjugated 
bilirubin could not be interpreted in view of the liver disease. Haemolysis, 
even if low grade, would have stimulated erythropoiesis and induced 
transcription of ALAS2 via erythroid transcription factors. It is unlikely that 
G6PD deficiency is of relevance to XLDPP in female subjects. 
Allthough DNA from subject EPP8.13 was not available for testing, an X-
linked inheritance pattern and the presence of affected sons establish her as 
bearing the c.1706-1709 delAGTG mutation. We therefore consider her the 
‘founding mother’ of the condition in South Africa. Biochemical features in 
support of a diagnosis of protoporphyria in her is limited to raised faecal 
porphyrins (Eales et al 1978). 
One of the features which distinguish XLDPP in family EPP8 from EPP is the 
high degree of disease penetrance. Indeed, Whatley et al (2008) describe 
“close to 100% penetrance” in XLDPP. However, some variation in the 
disease severity does occur as documented in Table 3. Subject EPP8.12 had 
a particularly fulminant disease with death at the age of 29. This is in contrast 
to apparent lack of phenotypic disease as noted in subject EPP8.13 and also 
in another obligate (but not confirmed) carrier described by Whatley et al 
(2008). Brancaleoni et al (2009) reported an asymptomatic XLDPP female 
with the ALAS2 deletion in an Italian family.  
Although XLDPP is inherited as an X-linked dominant condition, it would be 
anticipated that a gene dilution effect would cause affected females to exhibit 
decreased disease severity. Furthermore, in females skewed X inactivation 
may influence disease penetrance. Whatley et al (2008) did not record 
significant differences in PP concentrations between females and males, 
although liver disease was more prevalent in males. This is similar to liver 
pathology in family EPP8, where males have exhibited a more malignant 
disease course. 
102 
Liver disease in XLDPP, as in EPP, is considered secondary to accumulated 
PP toxicity (Poh-Fitzpatrick 1986, Whatley et al 2008). The exact factors 
leading to the development of liver disease in XLDPP, as in EPP, have not 
been clarified. Whatley et al (2008) note higher PP concentrations and a 
higher incidence of PP related liver disease in XLDPP than in EPP. It seems 
reasonable that PP induced liver disease is a function of mean PP 
concentrations over an affected individual’s lifetime, perhaps like 
microvasculopathy and blood sugar concentrations in diabetes mellitus. 
Ferrochelatase 
FECH has been shown to be normal in family EPP8, both at gene (Parker et 
al 2008) and enzyme (Chapter 4 of this dissertation) level. This is in keeping 
with the findings Whatley et al (2008) present for the other families with 
XLDPP. PP accumulation is ascribed to relative intra mitochondrial deficiency 
of iron as substrate, exemplified by ZnPP accumulation. However, as noted 
in Chapter 1, it has been suggested that FECH is capable of sensing 
intracellular iron concentrations via the Fe-S cluster (Taketani et al 2000), 
haem is reported to inhibit FECH activity (Dailey and Fleming 1983), and that 
erythroid FECH enzyme activity is decreased during intracellular iron 
deprivation (Crooks et al 2010). This may account for a fraction of the free 
PP which occurs in XLDPP, due to a reduction of in vivo FECH velocity 
beyond what would be expected from substrate deficiency alone.  
Gain in ALAS2 function 
The exact nature of the changes brought about by the mutations in ALAS2 
causing XLDPP, have not been elucidated. As noted in Chapter 5, the 
c.1706-1709 delAGTG mutation is predicted to cause a frame shift in 24
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codons and to extend ALAS2 by 4 amino acids (p.E569GfsX24). The c.1699-
1700 delAT mutation is predicted to result in a frame shift in 2 codons and to 
truncate ALAS2 by 20 amino acids (p.M567EfsX2). In both cases a marked 
increase in ALAS2 activity and porphyrin production in a prokaryotic 
expression system occurred (Whatley et al 2008). The activity and 
porphyrinogenesis of the c. 1699-1700 delAT mutant is higher than that of by 
the c.1706-1709 delAGTG mutant.  
The role of this highly conserved (Whatley et al 2008) C-terminal region in 
the regulation of ALAS2 activity is not known. It is possible that solving the 
crystal structure of human ALAS will help shed light in this regard. 
In essence, gain of function mutations in ALAS2 may either increase the 
amount of enzyme formed, or increase the catalytic activity of the enzyme 
either directly or indirectly. No kinetic data for XLDPP ALAS2 mutants are 
available.  
Enzyme formation may be regulated at the level of transcription (e.g. by 
promoter regulation), translation (e.g. by changes in the rate of translation or 
rate of mRNA degradation), or at the rate of ALAS2 enzyme degradation. If 
ALAS2 was subject to the same level of negative feedback regulation by 
haem as that which exists for ALAS1, haem overproduction in XLDPP would 
be expected to exert more effective control of ALAS2 activity.   
The location of the XLDPP mutations in the C-terminus of ALAS2, suggest 
possible stabilisation of ALAS2 mRNA or increased ALAS2 translation as a 
possible mechanism. It may be postulated than the XLDPP mutations may 
disrupt sequence(s) necessary for mRNA recognition by RNAase enymes or 
microRNA species. If the S568G substitution (Harigae et al 1999) does not 
disrupt this postulated recognition sequence, it would help explain why the 
S568G mutation located between the XLDPP mutations, causes a loss in 
ALAS2 function. However, this proximity of loss and gain in function 
mutations, remain an enigmatic and fascinating observation. 
MicroRNA characteristically binds in the 3’ mRNA UTR and may facilitate 
mRNA degradation or inhibit translation (Chu and Rana 2007). MicroRNA 
104 
binding in an exon has not been described, and if the XLDPP mutations were 
targets for microRNA regulation, this would be very unusual. 
ALAS2 c.1699-1709 is not a known target for microRNA regulation of ALAS2 
(as verified on http://microrna.sanger.ac.uk/cgi-
bin/targets/v5/detail_view.pl?transcript_id=ENST00000330807). At the time 
of writing, 7 microRNA species are known to target the ALAS2 mRNA 3’ UTR 
region. 
ALAS2 enzyme concentrations may be regulated by degradation velocity. 
Degradation of proteins is often mediated by the ubiquitin-proteosome 
system, in which ubiquitin tags proteins for further processing. An isopeptide 
bond forms between the C-terminus of ubiquitin and lysine residues on the 
ubiquitinated protein (Hurley et al 2006).  Mutations may abolish an 
ubiquitination site, thereby increasing ALAS2 enzyme half life. However, 
neither the c.1706-1709 delAGTG nor the c.1699-1700 delAT mutations are 
predicted to abolish a lysine residue, making this mechanism an unlikely 
cause for the gain in ALAS2 function in XLDPP.  
Haem catabolism 
The degradation of haem by haem oxygenase is competitively inhibited by 
ZnPP (Maines 1981). The physiological effect of ZnPP in XLDPP is not 
known but one may speculate that the accumulation of ZnPP would increase 
haem concentrations beyond that conferred by increased haem synthesis.    
At least 85% of mammalian CO is derived from haem degradation (Goldsmith 
and Landaw 1968). CO measurement allows the measurement of haem 
catabolism and haem oxygenase activity (Vreman and Stevenson 1988, 
Coceani et al 1997). This may be accomplished by carboxyhaemoglobin 
measurement in blood using co-oximetry (Mahoney et al 1993), or through 
CO measurement in expired air (Rodgers et al1994). It would be anticipated 
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that CO production in XLDPP would be elevated, assuming there was an 
increased production/accumulation of haem. 
Recommendations
It is useful to state some of the initial clinical recommendations we have 
formulated in order to inform and assist future encounters with patients 
suspected of, or confirmed to be affected by XLDPP. We advise the 
following: 
1. XLDPP should be considered in the differential diagnosis of all
patients presenting with clinical or laboratory features suggestive of
EPP. Clinical features which would suggest XLDPP include a highly
penetrant inheritance pattern, prevalence of liver disease and a
response to iron supplementation. Laboratory features suggestive of
XLDPP are a prominent or dominant ZnPP peak on erythrocyte
fluorescence emission scanning (a dominant free PP peak does not
exclude XLDPP, as seen with subject EPP8.2) and an inability to
demonstrate FECH mutations or enzyme dysfunction. The easiest way
of confirming a diagnosis of XLDPP is by direct sequencing of ALAS2
exon 11 (Chapter 5). Serum iron biochemistry showing
borderline/possible iron deficiency may suggest XLDPP but is not
discriminatory as some EPP patients, particularly women, may show
low serum iron and transferrin saturation.
2. Routine follow up by a clinician experienced in hepatology and
preferably porphyrinology. Clinical, biochemical and histological data
should be obtained and interpreted in the light of disease evolution,
bearing in mind that the life-threatening complications in XLDPP are
likely to result from liver disease. We noted in patient EPP8.2 that
serum liver function abnormalities tended to show a cholestatic pattern
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(with raised bilirubin, alkaline phosphatase and gamma glutamyl 
transferase) rather than a predominant transaminitis.  
3. Males should be monitored more closely as they are more likely to be
affected by severe disease.
4. Other factors which may portend a poorer prognosis may include
marked photosensitivity, a moderate (to marked) elevation in
erythrocyte PP concentration (arbitralily defined here as erythrocyte
PP concentration > 10 000 nmol/L), the manifestation of hepatic
complications at an early age and thrombocytopenia.
5. Treatment or management strategies resulting in lowering PP
concentrations should be considered. A sustained reduction in steady
state PP concentration, even if relatively minor, is anticipated to
decrease hepatic toxicity. The findings presented in the previous
chapter suggest that iron supplementation in XLDPP may have a PP-
lowering effect, but additional studies are required. Clearly,
supplementation resulting in iron overload is detrimental, and iron
toxicity, in excess of a reduction in PP toxicity, should be avoided.
Landefeld et al (2009) describe a case of a child with XLDPP who
developed liver siderosis during inadvertent blood transfusion-related
iron overload, accompanied by a marked reduction in erythrocyte and
liver PP. Thus frequent monitoring of serum iron studies during steady
state condtions outside of the acute phase response (due to e.g.
intercurrent illness) and in the absence of the confounding influence of
active liver disease, may be extremely useful in guiding cautious and
ongoing iron supplementation without causing iron overload.
6. Avoidance of sun exposure is obviously useful in reducing
photosensitivity symptoms and clearly effective in family EPP8.
7. General hepato-protective measures such as vaccination against viral
hepatitis and avoidance of toxins such as excessive ethanol intake or
hepatotoxic drugs.
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8. Ongoing genetic counselling is vital in ensuring all patients with
XLDPP understand the mechanism of disease transmission and the
risk to future generations.
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CHAPTER EIGHT 




Additional studies may be undertaken to clarify the pathophysiological 
changes associated with XLDPP. As family EPP8 are (mainly) resident in 
South Africa, a real clinical need exists for any additional information which 
may clarify the molecular pathogenesis further and assist in future 
management strategies. Prevention of liver disease is accepted as the 
primary goal of management.  
ALAS2 is exclusively expressed in erythroid cells. This fact, and the need to 
prove pathogenicity, prompted Whatley et al (2008) to use a prokaryotic 
expression system. Therefore the EBVTL culture lines used for the FECH 
enzyme assay described in Chapter 4 will not be suitable for ALAS2 
characterisation. 
Other suitable enzyme sources for studying ALAS2 may be developed. This 
could include murine erythroleukemia cells into which the mutation has been 
introduced. An XLDPP animal (e.g. murine) model would offer a vast number 
of opportunities for in vivo experimentation.  
ALAS2 characterisation in XLDPP 
This may be accomplished at enzyme activity, quantitative protein and mRNA 
concentrations. Such an approach would be similar to that originally 
proposed for the investigation of FECH in this dissertation. 
A prokaryotic expression system would be suitable for enzyme kinetic 
studies. KM and kcat could be determined for ALAS2 in WT and mutated 
states. A decrease in KM would signify a higher binding affinity for the 
substrate while an increase in kcat would suggest improved catalytic 
efficiency. Characterisation of various ALAS2 C-terminal engineered 
mutants could provide insight into how some mutations result in gain of 
ALAS2 function while others, such as the S568G substitution, cause loss 
thereof. 
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ALAS2 quantification may be accomplished by Western blotting. 
Relative gene expression of ALAS2 could be studied by conducting 
quantitative RT PCR of ALAS2 mRNA against a reference gene. Increased 
mRNA would imply increased mRNA or decreased degradation. Normal 
ALAS2 mRNA quantitation may still be compatible with regulation by a 
microRNA mechanism, if the mutant effect occurred by promoting translation 
of mRNA. 
Isoniazid (INH) is a known inhibitor of ALAS activity. The mechanism involves 
sequestering of pyridoxal in the hydrazone form, thereby preventing 
phosphorylation to the active pyridoxal phosphate (Mathews and van Holde 
1990). Investigation of ALAS2 activity and porphyrin production in an in vitro 
or animal XLDPP system during INH supplementation, would offer interesting 
information. Due to the potential toxic effects of INH (including peripheral 
neuropathy, vasculopathy and rarely convulsions), it is highly unlikely that 
INH would ever constitute an appropriate therapeutic agent in XLDPP. 
XLDPP penetrance in female subjects 
Skewed or non-random X chromosome inactivation is often postulated as a 
cause for varying disease penetrance in females with X-linked diseases. As 
noted in Chapter 7, this is the likely explanation for the lack of symptoms in 
subject EPP8.13. 
In female subjects with particularly severe or mild disease, this may be 
confirmed by a PCR reaction of the first exon of the human androgen 
receptor gene located on the X chromosome (Allen et al 1992).  This gene 
contains a highly polymorphic trinucleotide repeat sequence (distinguishing 
the maternal and paternal alleles) and a restriction site in close proximity. 
The restriction site is methylated during X-inactivation, abolishing its 
recognition by a methylation-sensitive restriction enzyme. The PCR primers 
flank both the trinucleotide repeat sequence and the restriction site.  Thus 
amplification will only occur if restriction digestion has not occurred, as 
expected from the inactivated allele. A random pattern of X inactivation is 
evidenced by PAGE visualisation of both the maternal and paternal 
 111 
amplicons. If only one band is detected, or if there is a marked difference 
between the bands, this would be in keeping with skewed X inactivation.  
Kubota et al (1999) developed an alternative method, which employs 
chemical modification of DNA by sodium bisulfite (converting all 
unmethylated - but not methylated - cytosine bases to uracil) and subsequent 
PCR of the human androgen receptor gene. This technique does not employ 
restriction enzymes (thus not vulnerable to incomplete restriction digestion) 
and uses 2 sets of primers – 1 for the methylated and the other for the 
unmethylated allele. The same polymorphic trinucelotide repeat utilised by 
Allen et al (1992) allows a ratio of the maternal allele to the paternal allele 
(for the methylated and unmethylated state), to be determined.  
Investigation of a control cohort revealed that 11% of normal females showed 
a skewed X-inactivation pattern (Kubota et al 1999).  
 
Haem catabolism 
Measurement of carboxyhaemoglobin concentration in blood (or CO in 
breath) in subjects from family EPP8 would suggest increased haem 
breakdown. Confounding influences such as smoke inhalation needs to be 
considered.  
Stool urobilinogen may be quantitated in order to investigate biliverdin 
formation by haem oxygenase. 
Supplementation with 13C glycine, quantified using mass spectrometry, 
would provide more direct evidence of increased haem synthesis and 
catabolism. An early (within days) peaked  13C stool urobilinogen would be 
expected in XLDPP with a later (~ 120 days) peak from senescent red cell 
breakdown. Normal controls are also expected to show peaks with a smaller 
initial peak and a similar sized later peak. A family of 4 signals obtained 
would confirm the tetrapyrrole origin of the signal, depending on the number 
of labeled glycine residues per ring. Interference from PP is possible 
although quantitatively the more hydrophobic PP undergoes significant 
enterohepatic circulation (Anstey and Hift 2007).   
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Alternatively, 14C glycine supplementation could be used in an animal model 
and stool radioactivity measured.  
Serum haemopexin concentrations in XLDPP could be assayed. Decreased 
concentrations would suggest increased serum free haem concentrations. 
This would be in keeping with increased free haem export from erythroid 
cells in XLDPP. 
Iron metabolism in XLDPP 
Examination of bone marrow iron stores remains a valuable and arguably 
gold-standard measure of iron stores. An animal XLDPP model would 
facilitate such examination of marrow iron content. 
During further iron supplementation of affected subjects from family EPP8 
(should it be indicated), red cell PP concentrations should be measured, as it 
was for subject EPP8.2 (Chapter 6). It would also be interesting to consider 
monitoring ZnPP : free PP ratios. Simultaneous reticulocyte indices would 
add further information regarding erythroid response to iron in XLDPP.  
Hepcidin measurement, aided by a recently characterised serum hepcidin 
immunoassay (Ganz et al 2008), may provide additional information 
regarding iron stores in XLDPP.  
Supplementation with 59Fe in an animal XLDPP model may reveal the fate of 
iron and where it is sequestered - if at all. The possibility of ongoing loss of 
iron as free haem via the bile in XLDPP, requires investigation. Measurement 
of stool 59Fe radioactivity would be useful in defining whether free haem is 
lost and so causes iron deficiency.  
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Summary and concluding remarks 
Details of the haem biosynthetic pathway and its regulation were reviewed in 
Chapter 1. In Chapter 2, the aim of the project was defined as a systematic 
inquiry into the molecular pathogenesis of an atypical protoporphyria in family 
EPP8. Exclusion of dysfunction of FECH at enzyme level was stated as an 
important initial objective. Relevant clinical details were elaborated in Chapter 
3. The establishment of a FECH enzyme assay, which showed normal
enzyme activity in affected subjects, was documented in Chapter 4. Chapter 
5 discussed the discovery of the gain in ALAS2 function which causes 
XLDPP. The finding of ALAS2 as the alternative disease locus resulted from 
international collaboration. Mutational DNA analysis of family EPP8 allowed 
genetic counseling and prediction of genetic risk. In Chapter 6, a treatment 
strategy in the form of iron supplementation was investigated. Data of 
porphyrin fluctuations during iron supplementation and hypotheses regarding 
iron metabolism in XLDPP were proposed. Some of the insights and 
conundrums that have emerged from this project and the findings of Whatley 
et al (2008) were addressed in Chapter 7. In the present chapter, future 
studies which may be undertaken to investigate XLDPP further, have been 
hinted at. 
A novel porphyria with unique features has been identified as being disease 
causing in family EPP8. Relative intra mitochondrial iron insufficiency in 
XLDPP, inadequate to match markedly increased PP synthesis, allows a 
possible explanation for many of the atypical features noted in Chapter 2.  
Regardless of the exact mechanism by which ALAS2 exon 11 mutations 
raise ALAS2 activity and perturb haem metabolism, the findings described 
here and by Whatley et al (2008), provide novel insights into how the haem 
biosynthetic enzyme and substrate systems, are regulated. 
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The unfolding of events and sequential discoveries documented in this 
dissertation, illustrates how in the general field of medicine, atypical disease 
features should never be ignored. The failure to identify a rational explanation 
for a disease manifestation should not preclude further exploration of the 
phenomenon. Whilst immediate resolution and explanation of unusual 
findings is part of conventional clinical and laboratory activities, in the case of 
XLDPP more extensive work was needed. Ongoing investigation resulted in 
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    Lennox Eales Porphyria 
Laboratories 
UCT/MRC Liver Research Centre 
Dept. of Medicine 
K-floor, Old GSH Building 
Observatory 
7925 
Tel: 27-21-406 6206 
Fax: 27-21-448 6815 
Department of Chemical Pathology 
Email: carel.haumann@uct.ac.za 







We would like to ask for your assistance in our investigation of Erythropoietic 
Protoporphyria (EPP). As you will be aware, EPP is caused by a decreased amount 
of Ferrochelatase enzyme. In the past you or members of your family, have 
been investigated for EPP. During Ms Parker’s study, the DNA sequence of your 
Ferrochelatase gene was investigated. 
                                               
 The Centre’s Mission is to better understand the liver and its’ related processes in health and disease, focusing on those diseases occurring in Southern 
Africa with a view to identification, prevention and improving health care of patients with liver disease 
 
The Mission of UCT is to be an outstanding teaching and research university, educating for life and addressing the challenges facing our society 
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In order to understand better how EPP in your family comes about, we aim to 
measure Ferrochelatase enzyme activity. In addition we plan to measure how 
Ferrochelatase enzyme is formed. This will form part of a thesis Dr Haumann 
will be writing. 
For this we would need another blood sample. This will also provide us with an 
opportunity to discuss any questions you might have about EPP. 
Our findings might help us understand EPP better. 
Thank you very much for considering this request. 
Yours sincerely 
Dr Carel Haumann 
Registrar 
Clinical Pathology NHLS and UCT 
A/Prof Peter Meissner 
Head, Porphyria Laboratories and Director UCT/MRC Liver Centre 
Dept of Medicine 
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APPENDIX C 
Porphyrin quantitation by chromatography 





Porphyrins are extracted from red cells and then esterified to methyl 
derivatives in acidic conditions. This decreases the overall polarity while 
retaining their relative polarity as conferred by carboxyl side chains.  After pH 
neutralisation (neutralising the charge on two of the four inner nitrogens), 
porphyrins are extracted into an organic solvent. Thin layer chromatography 
(TLC) distributes porphyrins between a polar solid phase and a non-polar 
mobile phase. The solid phase and the solvent compete for binding with the 
solute. The migration of porphyrins on the TLC plate is inversely proportional 
to the number of carboxyl groups, with uroporphyrin adhering to the solid 
phase closest to the application point, and PP travelling furthest. 
Fluorescence is quantified against standards. Incorporation of volume used 
allows the concentration to be calculated. The same technique, with minor 
modifications, may be used for red cell, plasma, urine and stool porphyrin 
quantification. Only the method used for red cell porphyrin quantification is 




Whole blood protected from light. EDTA anticoagulated blood does not show 
loss of porphyrins for 8 days at room temperature and 8 weeks at 4 °C in the 
dark (Deacon et al 2008). Approximately 1.5 ml of whole blood is needed, 





 Boiling tube with stopper 
 Separating flask  
 Glass funnel  
 Measuring cylinder 25 ml  
 TLC plates (TLC aluminium sheets 20X20cm Silica Gel-60, without 
fluorescent indicator, Merck Chemicals) 
 Hamilton microsyringe 
 A selection of pipettes and tips 
 Fluoroscanning photodensitometer TLD 100 (Vitatron) 





 Sulphuric acid (H2SO4)  
 Methanol (CH3OH)  
 Chloroform (CHCl3) 
 Ammonia solution (NH4OH)  
 Anhydrous sodium sulphate (Na2SO4) 
 Porphyrin methyl ester calibrator - equal concentrations of uroporphyrin, 
heptacarboxylic porphyrin, hexacarboxylic porphyrin, pentacarboxylic 
porphyrin, coproporphyrin and mesoporphyrin methyl esters (Frontier 
Scientific Porphyrin Products) 
 Carbon tetrachloride (CCl4) 
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 Dichloromethane (CH2Cl2)  
 Ethyl acetate (CH3COOC2H5) 
 Ethyl propionate (C5H10O2)  
 n-Dodecan (C12H26) 
 n-Hexadecan (C16H34) 




1. Add 500 µl of packed red blood cells and 30 ml 5% sulphuric acid in 
methanol (v/v) to a boiling tube.  
2. Close with a stopper, shake and leave to esterify overnight in the dark.  
3. Rinse a separating flask with methanol:chloroform::50:50 (v/v) and add 60 
ml 4% ammonia and 10 ml chloroform in a fume hood.  
4. Centrifuge the esterified sample at 280 xg for 20 min and transfer the 
supernatant to the separating flask and seal. 
5. Shake flask vigorously for 5 - 20 sec intervals, releasing gaseous build-up 
intermittently. 
6. Fill the flask to ¾ its volume by adding ~ 150 ml H20. Stir and allow the 
heavier chloroform organic phase to settle at the bottom of the flask.  
7. Rinse a funnel with chloroform and place below the flask in a measuring 
cylinder. 
8. Add ~ 2 g of anhydrous sodium sulphate to the funnel. This binds and 
removes any residual H20. 
9. Allow the chloroform to run through the funnel into the measuring cylinder. 
Repeat after adding 10 ml chloroform.  
10.  Note the volume of chloroform eluted. Spot 60 µl (the spotted volume 
may be decreased to remain within the linear part of the fluorescence 
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concentration curve if large quantities of porphyrins are anticipated) onto 
a TLC plate using a Hamilton microsyringe ~ 1 cm from the base of the 
plate and with 2 cm between lanes. Evaporate the chloroform to dryness 
with warm air, e.g. using a conventional hair-drier. 
11.  Reserve two lanes on each plate for porphyrin ester standards. 
12.  Run the TLC plate vertically in a chromatography tank containing 180 ml 
mobile-phase solvent (carbon tetrachloride:dichloromethane:ethyl 
acetate:ethyl propionate::2:2:1:1 (v/v)) for 40 min or until the solvent front 
reaches the top of the plate. 
13.  Dry the TLC plate and dip briefly in a fluorescence enhancing solution 
containing chloroform:n-dodecan:n-hexadecan::3:1:1 (v/v). 
14. Dry and read the plate on a fluoroscanning photodensitometer connected 
to an integrator/recorder unit using two interference filters (excitation filter 
at 399 nm; emission filter at 620 nm).  
15.  This produces a trace showing the porphyrin ester position and 
fluorescence (graphically and a numerical value corresponding to the 




Standards allow porphyrin species to be identified and quantitated by their 
position and fluorescence intensity, respectively. The pattern of porphyrin 
species identified, allows the likely type of porphyria to be inferred. 
Quantitative results are expressed in nmol/L.  Red cell PP reference range = 







The general equation Asample/Astd = (Csample x Vsample) / (Cstd x Vstd) is used 
where A = area of peak (analogous to absorbance), std = standard, C = 
concentration and V = volume. This is the equation from which the very well-
known equation C1 x V1 = C2 x V2 is derived.  
The sample was diluted by a factor (packed red cell volume) / (final 
chloroform volume).  In order to calculate the initial red cell concentration this 
































Qualitative zinc and free protoporphyrin 
fluorescence scanning 





ZnPP and free PP have distinct fluorescence emission maxima at 588 nm 
and 632 nm, respectively. Emission fluorescence scanning may be used to 
determine which PP specie predominates. More specific information on the 
percentage contributed by the two species to the total PP pool may be 
calculated by additionally measuring fluorescence at the isosbestic point at 




Whole blood protected from light. EDTA is generally used as anticoagulant. 





 Glass tube  
 Fluorescence spectrophotometer 650-10S (Hitachi Koki) 
 Linear 1200 chart recorder (Spectrum Medical Industries) 
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 150 Xenon Power Supply (Perkin-Elmer) 
 Quartz cuvette (acetone will damage plastic) 
 A selection of pipettes and tips 





 0.9% NaCl   




1. Make a 1 in 10 dilution of 20 µl of packed red cells in a glass tube. 
2. Add 5 ml of 80% acetone. 
3. Vortex for 30 sec. 
4. Centrifuge at 700 xg for 1 min. 
5. Transfer 1 ml of the supernatant to a quartz cuvette for fluorimetry.  
6. Perform an emission scan from 540 nm to 650 nm with excitation at 420 
nm, sensitivity of 10, slit width 4.5 nm and a scan speed of 60 nm/min. If 
necessary, adjust sensitivity to include entire peak. 
7. Record a profile of the scan on a chart recorder (chart speed: 3 cm/min) 






If the main peak is at 588 nm, EPP is unlikely. A dominant peak at 632 nm is 
highly suggestive of EPP.  
 
Calculation  






























Epstein-Barr virus lymphocyte transformation 






Lymphocytes are isolated from peripheral blood by centrifugation over a 
Ficoll-hypaque density gradient. EBV is introduced into the mixed lymphocyte 
suspension and B lymphocytes are infected, giving rise to an immortalised 
lymphoblastoid cell line. EBV particles are derived from the transformed 
marmoset monkey B95-8 cell line. Transformation is aided by T lymphocytes 
stimulation via phytohaemagglutinin (PHA).  EBVTL are continued in culture, 
initially with antibiotic cover, and then later in duplicate without antibiotics, 
until sufficient cells are available for enzyme assay. Sterility is of utmost 
importance to prevent infection of the culture with Mycoplasma species and 
other organisms. The duplicate culture is conducted with separate media 
from 2 different manufacturers to decrease the risk of infection or culture 
failure. Cell growth is assessed by macroscopic and microscopic inspection. 
EBVTL may be seen microscopically as colonies of cells growing in clumps. 
An indicator in the medium may also help to assess growth by changing from 
pink to yellow as the pH declines with active cell metabolism. During culture, 
EBVTL require an appropriate cell concentration in culture medium. Both 
overdilution and overgrowth of EBVTL may result in culture failure, due to 
loss of culture conditioning and nutrient deficiency/metabolite excess, 





10 ml of whole blood collected into heparinised tubes within 24 h (ideally) or 
up to 48 h after venesection. If 10 ml blood is not available, make an initial 
dilution with an equal volume of culture medium. Paediatric samples contain 
more lymphocytes and less blood is required (2 – 5 ml sufficient). A culture 
that is initiated with a suboptimal quantity of lymphocytes will be slower to 





 Tissue culture hood (Biological safety cabinet class II, Laminaire) 
 Incubator (Queue) 
 CO2 supply 
 Centrifuge 
 Pipet-Aid pipettor with disposable, individually wrapped sterile 5 and 
10ml pipettes 
 15 ml Conical tubes 
 50 ml Conical tubes 
 25 cm2 Culture flasks 
 75 cm2  Culture flasks 
 2 ml  Cryotubes 
 0.22 µmetre (µm) filter discs 
 Filter paper (Whatman number 1) 
 Phase contrast microscope with green filter (Nikon TMS) 
 Fluorescent microscope (Zeiss Axiophot) 




 Marmoset B95-8 cell line stored at -180 °C under liquid nitrogen 
  Dulbecco’s modified Eagle’s medium (Gibco) stored at 4 °C 
  Dulbecco’s modified Eagle’s medium (Sigma) stored at 4 °C 
 Fetal Calf Serum (Gibco) stored at -20 °C 
 Fetal Calf Serum (Sigma) stored at -20 °C 
 Glutamine solution 200 mmol/L (Gibco) stored at -20 °C 
 0.9% NaCl solution 
 Neomycin sulphate (powder) 
 Streptomycin sulphate (powder) 
 Sodium Benzyl Penicillin (powder) 
 PHA (Welcome) 
 Trypan blue 
 Hoechst solution 5 mg/100 ml 
 Hanks Balanced Salt Solution (without Na bicarbonate or phenol red) 
– phosphate buffered saline may be used as alternative  
 Citric acid [(COOH)3CH2CH2COH.H20] 
 Disodium hydrogen phosphate (Na2HPO4.2H20) 
 Glycerol 
 Reagent grade H20 





Preparation of solutions and media 
 
1) Culture medium 
To 500 ml modified Eagle’s medium, add 50 ml (10%) fetal calf serum from 
the corresponding manufacturer. Prepare separate culture media from Gibco 
and Sigma to be used for two parallel cultures. Additionally, in the case of the 
Sigma medium, add 10 ml of the 200 mmol/L glutamine solution to the 500 
ml modified Eagle’s medium.  
 
2) Antibiotics 
Add 2 g neomycin, 2 g streptomycin and 2 g penicillin to 100 ml sterile 0.9% 
NaCl. Add 2.5 ml of this solution to 500 ml culture medium (final antibiotic 
concentration 100 units/ml). Prepare the antibiotic-containing culture medium 
separately for use only during the initial culture phase. 
 
3) EBV medium 
Thaw and grow an aliquot of the marmoset B95-8 cell line in a 75 cm2 flask. 
Once sufficient cells are available, centrifuge 50 ml medium in a conical tube 
for 10 min at 168 g. Filter the supernatant through a 0.22 µm filter (thus 
removing marmoset cells) and add an equal quantity of fresh culture medium. 
This may be stored for 6 months at 4 °C.  Caution: EBV medium (but not 
EBVTL) represents a source of potential infection with EBV to the operator. 
Demonstration of serum anti-EBV IgG before working with EBV medium is 
desirable. Studies have shown that 95% of adults are infected with EBV 
benignly for life (in vivo, EBV achieves true latency and is kept in check, but 






Dissolve 1 mg PHA in 5 ml reagent grade H20. Make a 1 in 5 dilution with 
0.9% NaCl. Filter though a 0.22 µm filter disc. Add 500 µl to 10 ml culture 
medium to a final concentration of 2 mg/L.  
 
5) Trypan blue 
Prepare a 2% solution in reagent grade H20. Pour through filter paper. Take 
equal volumes of 2% trypan blue and 0.9% phosphate buffered saline, mix 
and centrifuge at 4000 g for 10 min. Aspirate 1% trypan blue ~ halfway from 
the bottom of the centrifuge tube to avoid debris. Mix 7 parts 1% trypan blue 
with 30 parts 3% EDTA / 0.9% phosphate buffered saline. The working 
solution (0.189% trypan blue) may be stored for 2 weeks at 4 °C.   
 
6) Hoechst stain 
Prepare by adding 1 ml of Hoechst solution to 99 ml Hanks Balanced Salt 
Solution to a final concentration of 0.5 mg/L. This is stored in a dark bottle at  
4 °C. Do not filter the stain as this removes the fluorescent dye.  
 
7) Mounting fluid: citric acid – disodium phosphate buffer 
 Prepare a 0.1 mol/L citric acid solution by dissolving 1.05 g citric acid 
in 50 ml reagent grade H20. 
 Prepare a 0.2 mol/L disodium phosphate solution by dissolving 1.41 g 
disodium phosphate in 50 ml reagent grade H20. 
  Add 22.2 ml of the citric acid solution, 27.8 ml of the disodium 
phosphate solution to 45 ml of glycerol, pH to 5.5 and make up to 100 
ml with reagent grade H20. Note: the correct pH is vital for generating 





(Sterile technique with use of the tissue culture hood and fan, ethanol to 
clean hands and sterile equipment throughout essential) 
 
 Centrifuge 10 ml whole heparinised blood for 5 min at 1400 xg. Draw 
buffy coat and plasma into a 10 ml pipette and mix.  
  Layer plasma/ buffy coat onto 5 ml of Ficoll-hypaque.  
 Centrifuge at 1400 xg for 20 min. Any residual red cells and 
neutrophils will fall through the Ficoll-hypaque gradient while some 
monocytes, platelets and lymphcytes will be found in a creamy layer 
between Ficoll and plasma. Remove lymphocytes from this 
intermediate layer. Avoid drawing up too much Ficoll in the process.  
 Suspend lymphocytes in 5 - 8 ml culture medium and centrifuge at 170 
xg for 10 min. Repeat once.  
 If lymphocytes are being isolated for direct use in the FECH assay (i.e. 
without transformation) 0.9% saline may be used to wash in stead of 
culture medium. In this case, proceed to Appendix F and G by 
suspending the lymphocyte pellet in sonication buffer.   
 Suspend washed lymphocytes in 5 ml EBV-containing medium and 
transfer to a 25 cm2 flask. Add 0.25 ml PHA and incubate (with the 
flask in a vertical position) at 37 °C in a 10% CO2 environment. The 
same incubation conditions are continued for the remainder of the 
culture process. Flasks should only be capped lightly to allow CO2 to 
equilibrate with the bicarbonate buffer in the culture medium.  
 After 3 days, remove 2.5 ml medium and add 2.5 ml fresh culture 
medium containing antibiotics.  
 Assess cell growth every 3 - 4 days. Cells will tend to precipitate to the 
bottom of the flask. EBVTL concentration may thus be increased by 
removing medium. This is done if growth appears poor to improve the 
conditioning of the medium. Conversely, if abundant growth is present, 
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new medium (2 - 5 ml) may be added. In an intermediate situation, 
existing medium may be removed and an equal volume of fresh 
medium added. 
 Once the culture is becoming established, place the 25 cm2  flask in a 
horizontal position.  
 Split the culture into 2 parallel cultures with different media. Antibiotics 
may be discontinued. 
 Once culture growth allows, transfer 10 ml into a 75 cm2 culture flask, 
add 10 ml of fresh medium and incubate the culture with the flask in a 
vertical position. Once this is established, double the culture volume 
by adding an equal volume of fresh medium and position 75 cm2  flask 
horizontally. 
 Abundant quantities of EBVTL should now be available for 
enzyme/RNA assay or freezing under liquid nitrogen at - 180 °C for 
later use.  




It is imperative that enzymes or RNA subjected to assay are derived from 
viable cells. Assay of dead or infected cells may result in spurious results. 
 
1) Phase contrast microscopy 
Under phase contrast microscopy, viable EBTVL may be seen as glossy 
structures of variable shape, usually arranged in clumps or rosettes. The 
phase contrast light generates a slight halo. In contrast, dead cells appear as 
uniformly darker, shrunken structures without a halo. A green filter improves 
the contrast effect.  
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2) Trypan blue exclusion test 
Place a drop of an equal mixture of EBVTL in culture medium and 0.189% 
trypan blue on a slide, apply a cover slip, and examine under a microscope 
(preferably phase contrast) without a green filter. Viable cells do not take up 
trypan blue while dead cells do. A maximum of 5% blue (i.e. dead) cells 
should be seen. Avoid an undue delay between preparing the trypan 
blue/EBVTL mixture and examining the slide. 
 
3) Hoechst fluorescent staining for Mycoplasma infection 
Exclude Mycoplasma infection by placing a drop of EBVTL-containing culture 
medium on a slide, air drying, fixing with an acetic acid: methanol::1:3 (v/v) 
solution for 20 sec, and washing under tap H20. Apply the Hoechst stain for 
20 sec, wash under tap H20, apply a cover slip with 1 drop of mounting fluid 
and examine under a fluorescent microscope.  The Hoechst stain shows up 
nuclear material. Mycoplasma species, if present, will be seen as green dots 
in the EBVTL cytoplasm, around the nuclei. Bacterial nuclei may also be 
seen, around the EBVTL.    
 
 
Storage of cells under liquid nitrogen 
 
 Cells should only be stored once infection has been excluded. 
 The freezing process is structured to allow a gradual temperature 
decline in order to prevent crystal formation and cell rupture, aiming 
for 1 °C per min.  
 Allow cells to gather at the bottom of a 75 cm2  flask  and discard the 
supernatant, leaving only about 10 ml at the bottom of the flask. 
 Transfer the 10 ml EBVTL-containing medium to a conical tube. 
 Top up with culture medium to 15 ml and centrifuge for 10 min at     
110 xg. Discard the supernatant, add 5 ml culture medium and repeat 
centrifugation. 
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 Again discard the supernatant and suspend EBVTL in 7 ml freezing 
medium consisting of Dulbecco’s modified Eagle’s medium with 20% 
Fetal Calf Serum and 10% glycerol. 
 1 ml aliquots are placed into cryotubes. 
 Place cryotubes in the nalgene freezing container in the presence of 
250 ml propyl alcohol at -80 °C for at least 4 h. 
 Finally, the cryotubes may be transferred to the -180 °C freezer and 
stored under liquid nitrogen. 
 Thawing, in contrast to freezing, is conducted rapidly by placing an 
EBVTL-containing cryotube in H20 at 40 °C immediately after removal 
from the liquid nitrogen. Following this, the 1ml of EBVTL-containing 
medium is added to 5ml of culture medium which has been warmed to 
37 °C and pre-equilibrated with CO2 for a few h. After 3 days, the 









Bradford (Bio-Rad) protein assay 





Binding of protein to Coomassie Brilliant Blue dye at a constant pH results in 
a shift in the absorbance from 465 nm to 595 nm. This results in the mixture 
becoming a deep blue colour. The dye binds to protonated amine groups of 
the protein in an acidic medium. This method is based on the ‘protein error of 
indicators’ principle which relates the hydrophobic interior of proteins to the 
change in indicator colour. The Beer-Lambert Law is used to calculate the 
concentration of the sample using a standard curve. It is well known that the 
Beer-Lambert Law breaks down at a high absorbance (e.g. absorbance > 
1.2). Conversely, precision is compromised at an absorbance < 0.1. The 
standard curve is thus constructed to fall within the linear range. Samples are 





EBVTL or lymphocyte sonicate in sonication buffer is used. However, this 
method may be used to determine the protein content of virtually any 
appropriately diluted fluid with sensitivity. 






 Spectrophotometer (Beckman DU 640) 
 2 Flasks  
 Funnel 
 Vortex mixer 
 A selection of pipettes, tips and test tubes 
 Cuvette (plastic is suitable) 




 Bio-Rad reagent (Bio-Rad Laboratories) containing dye, phosphoric acid 
and methanol 
 Bovine serum albumin 1 mg/ml standard – stored in aliquots at -80 °C 




Guard against residual glassware contamination by protein as this method is 
highly sensitive.  “Standard” and “microassay” procedures are described in 
the Bio-Rad package insert. The method described here is a scaled-down 
version of the “standard” procedure, found to be most convenient.   
1. Estimate the final volume of Bio-Rad reagent required.  
2. Prepare the Bio-Rad reagent by diluting 1 in 5 with reagent grade H20. 
Filter through filter paper placed in a funnel.  
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3. Prepare standard blank (reagent grade H20) and 5 bovine serum albumin 
dilutions in a range of concentrations (as indicated below) in triplicate. 
The final volume in each tube is 50 µl. 
4. Prepare sample blank (using sonication buffer as used in FECH enzyme 
assay) and sample dilutions in triplicate. The sample blank is diluted in 
the same way as the sample with H20 (separate blanking for sample 
necessary to correct for any background absorbance from buffers present 
in sample and not in standard). The final volume in each tube is 50 µl.   
5. To each blank, standard and sample add 2.5 ml diluted Bio-Rad reagent. 
Vortex, avoiding foaming, and allow to stand. 
6. Read absorbance at 595 nm after 5 min and within 1 h. Blank on the 




An example of standards, blanks and one sample (sample A) is presented in 
Table 9 showing dilutions, typical values obtained and standard curve 











Table 9: Example of data used to generate sample A protein concentration 
















Blank 0 50 0   0  - 
0.100 5 45 0.1561 0.1634 0.1538 0.1578  100 
0.200 10 40 0.3047 0.3099 0.2942 0.3029  200 
0.400 20 30 0.5115 0.5148 0.5123 0.5128  400 
0.600 30 20 0.7051 0.6920 0.7187 0.7053  600 
Sample 
Sample 
Blank 15 35 0.0094     - 
Sample A 15 35 0.4389 0.4478 0.4458 0.4348 50/15 1113 
 
Protein standard curve using bovine serum albumin


































The regression equation is shown on the standard curve graph and the 
following may be derived for this standard curve:  
Concentration = (absorbance/1.0783) – 0.0693  
The sample is diluted in order to fall within the linear range on the standard 
curve and to make the final volume up to that of the standard. The initial, 
undiluted concentration of the sample is the desired parameter. Therefore, 
correction for sample dilution by means of a dilution correction factor is 
necessary.  
Sample A protein concentration:  
= (0.4348/1.0783 – 0.0693) x 50/15 = 1.113 mg/ml protein 
= 1113 mg/L protein 
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APPENDIX G 
FECH enzyme assay 





An EBVTL or lymphocyte sonicate is used as source of FECH to quantify 
enzyme activity by measuring the formation of Zn meso fluorometrically per h 




EBVTL in tissue culture medium is used. Volume used will depend on EBVTL 
concentration but generally 10 ml is used. Lymphocytes may also be used: 
10 ml of whole blood contains sufficient lymphocytes for assay.  




  Misonix sonicator 3000 (Lasec) 
 Fluorescence spectrophotometer 650-10S (Hitachi Koki) 
 Spectrophotometer (Beckman DU 640) 
 Centrifuge 
 Microcentrifuge 
 Balance: 5 place (Sartorius Research) 
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 pH meter 
 Magnetic stirrer 
 Vortex  mixer 
 Water bath 
 Timer 
 A selection of pipettes, tips, 2 ml microcentrifuge tubes, glass tubes and 
beakers 
 15 ml conical tube 
 Glass tubes 
 Quartz or glass fluorimetry cell  
 
Reagents 
 Tris (Tris(hydroxylmethyl)aminomethane) ((HOCH2)3CNH2: MW 121.1) 
 Hydrochloric acid (0.1 N, 2.7 N, 5 N HCl solutions) 
 Glycerol 
 NaCl (0.9%) 
 Triton X-100  
 Palmitic acid (CH3(CH2)14 COOH: MW 256.4) 
 Mesoporphyrin IX dihydrochloride (C34H40N402.Cl2: MW = 639.62) 
(Frontier Scientific, catalogue number M566-9, 100 mg) 
 Zn2+ mesoporphyrin IX (C34H36N4O4Zn: MW = 630.06) (Frontier Scientific, 
catalogue number M-40628, 25 mg) 
 Zinc acetate Zn ([CH3COO]2.2H20: MW 219.5) 
 DMSO ((CH3)2SO) 
 Methanol (CH3OH) 
 Reagent grade H20 
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Preparation of solutions / buffers 
1. Sonication buffer 
A 50 mmol/L Tris buffer at pH 7.6 with 20% glycerol is prepared as follows:   
 Dissolve 606 mg Tris in 60 ml reagent grade H20 
 pH to 7.6 with 5 N HCl 
 Add 20 ml glycerol 
 Add reagent grade H20 to a final volume of 100 ml in a 
volumetric flask. 
 
2. Enzyme sonicate 
 Centrifuge suspension of EBVTL in culture medium in a conical 
tube at 170 xg for 10 min. 
 Pour off culture medium. Suspend and mix pellet carefully in 10 ml 
0.9% NaCl and centrifuge as before. Repeat once.  
 Finally suspend the pellet in 800 µl sonication buffer.   
 Cool lymphoblast suspension on ice. 
 Sonicate suspension for 20 sec with a microprobe at 3 watt. 
 Cool sonicate again on ice. 
 
The sonicated enzyme preparation is stable at 4 °C for 24 h. In the case of 
heavy EBVTL growth, it is preferable to perform the protein assay (see 
Appendix F) prior to the enzyme assay. This allows appropriate sonicate 
dilutions to be made. The assay is linear up to 1000 mg/L protein (Rossi et al 
1988) and 200 – 600 mg/L was used during the investigations described 
here.   
The sonication buffer is used as blank during the enzyme assay.  
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3. Incubation buffer 
A 250 mmol/L Tris solution with 1% Triton X-100 and 1.46 mmol/L palmitic 
acid is prepared as follows: 
 Dissolve 1 ml Triton X-100 and 3029 mg Tris in 20 ml H20 and mix 
well.  
 Add 37.4 mg palmitic acid and sonicate liberally until 
macroscopically dissolved. Magnetically stir for 1hr. Dissolving the 
palmitic acid is slow and is aided by the high pH and Triton-X 
concentration before adjusting the pH and volume. The final 
reaction palmitic acid concentration is 0.76 mmol/L, including the 
palmitic acid in the reaction buffer and in the mesoporphyrin.  
  Add reagent grade H20 up to 80 ml and pH to 7.6 with 5 N HCl. 





Prepare a 0.5 mmol/L solution as follows: 
 Carefully weigh out 1 mg of mesoporphyrin and dissolve in 3127 µl 
incubation buffer. It is easier to weigh out an aliquot of ~ 1 mg, to 
note its exact mass, and to calculate the volume of buffer to add as 
follows: 
Volume in µl = [(mass in mg)/ (639.62 x 0.5)] x 106 
 
 Stir magnetically for 1 h covered by parafilm and tinfoil and verify 
visually that all mesoporphyrin has dissolved. 
 Spectrophotometry may be used to quantitate the mesoporphyrin 
concentration. The millimolar extinction coefficient for 
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mesoporphyrin at 399 nm in 0.1 N HCl is 445 L/mmol/cm (Falk 
1964): 
o Add 980 µl 0.1 N HCl to 20 µl mesoporphyrin.  
o Add 200 µl of the above to 1800 µl 0.1 N HCl.  
o The total dilution is 1 in 500 (to a concentration of 1 µmol/L). 
 Measure absorbance spectrophotometrically at 399 nm, blanking 
against 0.1 N HCl.  
 
Concentration of mesoporphyrin = (absorbance x 500)/445 
 
b. Zinc 
A 1 mmol/L solution is prepared by dissolving 22 mg zinc acetate in 100 ml 
reagent grade H20. 
 
5. Stopping solution 
Prepare a 30/70 (v/v) solution by adding 30 ml DMSO to 70 ml methanol 
in a fume hood. Store in a darkened glass bottle. Caution: DMSO is 
minimally toxic but may penetrate skin, carrying other compounds with it. 
Gloves are essential. Dispose of this solution in a chemical waste 
container. 
 
6. Zn meso standard 
 Prepare a 0.5 mmol/L solution as follows: carefully weigh out 1 mg 
of Zn meso and dissolve in 3174 µl stopping solution. It is easier to 
weigh out an aliquot of ~ 1 mg, to note its exact mass, and to 
calculate the volume of stopping solution to add as follows: 
 
Volume in µl = [(mass in mg)/ (630.06 x 0.5)] x 106 
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 Stir magnetically for 10 min covered by parafilm and tinfoil. 
 Although careful weighing and volume calculation as described 
above is essential in making up the Zn meso standard accurately, 
the final concentration of Zn meso is determined 
spectrophotometrically. For this purpose the mesoporphyrin 
extinction coefficient in 0.1 N HCl at 399 nm is used after first 
converting Zn meso to mesoporphyrin by acidification. 
o Use glass tubes for dilutions.   
o Add 50 µl Zn meso solution to 950 µl 2.7 N HCl (1 in 20 
dilution). 
o Allow incubation for 10 min covered by parafilm and tinfoil. 
o Add 100 µl of the Zn meso/HCl solution to 2600 µl reagent 
grade H2O (1 in 27 dilution). 
o Measure absorbance spectrophotometrically at 399 nm, 
blanking against 0.1 N HCl.  





Perform the assay in triplicate. Use 2 ml microcentrifuge tubes (if possible, to 
aid mixing) and add the following: 
Sonicate (diluted if appropriate; sonication buffer for blank) 200 µl 
Incubation buffer       200 µl 
Mesoporphyrin (0.5 mmol/L)     40 µl 
 Preincubate in water bath at 37° C for 5 min. 
 Add 20 µl zinc acetate (1 mmol/L) solution and mix. 
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 Continue incubation in a shaking waterbath at 37 °C for 60 min. 
 Terminate the reaction by adding 1000 µl DMSO/methanol stopping 
solution, up to a final volume of 1460 µl. 
 Centrifuge at 13 000 xg in a microfuge for 3 min. 
 Transfer 1000 µl supernatant into a quartz or glass fluorimetry cell.  
 Measure fluorescence using the following settings: 
o Slit width 5 nm 
o Sensitivity 1 
o Excitation 410 nm 
o Emission 580 nm 
o Fluorescence blanked on the stopping solution 
 The stopping solution destroys enzyme activity (and aids porphyrin 
solubilisation) but does not prevent non-enzymatic autochelation of zinc 
by mesoporphyrin. Thus, undue delays after addition of the stopping 
solution until fluorescence measurement should be avoided.  
 
 
2) Zn meso standard curve construction 
 Use the 0.5 mmol/L (500 000 nmol/L) Zn meso solution to prepare a 
series of dilutions with the stopping solution. 
 Use glass tubes. 
 Add 100 µl Zn meso to 900 µl stopping solution = 50 000 nmol/L (1 in 10 
dilution). 
 Add 100 µl 50 000 nmol/L Zn meso to 900 µl stopping solution = 5000 
nmol/L (1 in 10 dilution). 
 Add 300 µl 5000 nmol/L Zn meso to 4700 µl stopping solution = 300 
nmol/L (1 in 16.6 dilution). 
 Prepare further dilutions as indicated in Table 10: 
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Table 10: Dilutions used for Zn meso standard curve 
Volume of 300 
nmol/L solution (µl) 
Volume of stopping 
solution (µl) 
Final Zn meso 
concentration (nmol/L) 
1000  0 300  
800  200  240  
600 400  180  
400  600  120  
200  800  60  
100  900  30  
0 1000  0  
 
 Record fluorescence in RFU. 
 Plot RFU against concentration using Microsoft Excel. 
  A regression equation is derived which allows fluorescence generated 




Typical values recorded during the standard curve construction (Figure 33) 
are shown in Table 11: 
 The centre column shows the Zn meso concentration corrected to the Zn 
meso concentration as determined spectrophotometrically.  
 In this case, the spectrophotometrically determined concentration of the 
primary Zn meso solution was found to be 0.48 mmol/L (as opposed to 
the concentration it was made up to of 0.5 mmol/L). The values in the 
centre column were derived by multiplying the concentration in the left 





Table 11: Example of data used for Zn meso standard curve 
construction 
Zn meso conc 
(nmol/L) 




0 0 0 
30.0 28.8 133 
60.0 57.6 242 
120.0 115.2 504 
180.0 172.8 745 
240.0 230.4 955 
300.0 288.0 1184 
Figure 33: Zn meso standard curve and regression equation 
Zn Meso standard curve at 580nm
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 Example of fluorescence recorded after 1 h of FECH activity at 37 
°C  : 
 RFU blank = 140  
 RFU1 sonicate = 600 
 RFU2 sonicate = 615 
 RFU3 sonicate = 627 






∆RFU = RFU sonicate – RFU blank 
           = 474 
Thus Zn meso formed per h       = (474-12.884)/4.1138 
                                                        = 112.1 nmol/L/h  
But the sonicate enzyme activity has been diluted by 1460/200  
                                                        = dilution factor of 7.3  
Thus corrected Zn meso formed      = 884.0 nmol/L/h 
Protein in sonicate (determined via Bradford method, Appendix F) 
                                                         = 720 mg/L      
And incubation time = 1 h 
Thus FECH activity at 37° C   = 884.0 (nmol/L/h) / [720mg/L x 1 h]  
                                                   = 1.23 nmol Zn meso/h/mg protein    
(h)  time(mg/L) sonicateprotein 
(nmol/L) sonicate meso/L Zn nmol






DNA extraction  
using Wizard® Genomic DNA Purification kit (Promega) 





Leukocytes are separated from whole blood by centrifugal pelleting after red 
cell lysis. After separation, the leukocyte nuclei are lysed, releasing DNA. 
Protein is removed by salt precipitation, the saturated salt solution driving 
protein out of aqueous solution. The negative charge on the phosphate 
backbone is capable of keeping DNA in solution under these conditions. The 
addition of isopropanol causes DNA to precipitate out by excluding water 
molecules.  Finally, 70% ethanol is used to wash away residual salt while 




Whole blood is used. Conventionally, EDTA anticoagulated samples are 
used for DNA/RNA studies. The package insert states that heparin and 
citrate are also acceptable anticoagulants. However, heparin is generally 
understood to interfere with the PCR and the use of heparin as an 
anticoagulant in this context was not verified here.  
Starting volumes of 20 µl – 10 ml of whole blood may be utilised, provided 





 Vortex mixer 
 Microcentrifuge 
 Heating block  
 A selection of microcentrifuge tubes, dedicated pipettes and filter tips 





 Wizard® Genomic DNA Purification Kit (Promega) containing Cell Lysis 
Solution, Nuclei Lysis Solution, Protein Precipitation Solution and DNA 
Rehydration Solution 
 Isopropanol (CH3CHOHCH3)  





 In view of the sensitivity and the amplification inherent in a PCR reaction, 
avoidance of contamination is of paramount importance. Working in a 
DNA extraction area is advised. The most hazardous form of 





1. Allow samples to come to room temperature and mix. 
2. Add 300 µl whole blood to 900 µl of Cell Lysis Solution in a 
microcentrifuge tube and mix by inversion.  
3. Incubate for 10 min at room temperature. 
4. Centrifuge at 16 000 xg for 2 min.  
5. Discard supernatant. 
6. If red cell contamination is visible in pellet, repeat steps 2-5. Haemoglobin 
partially inhibits PCR. 
7. Vortex pellet. 
8. Add 300 µl Nuclei Lysis Solution to the microcentrifuge tube and mix by 
inversion. 
9. Add 100 µl Protein Precipitation Solution to the microcentrifuge tube and 
vortex for 20 sec. 
10. Centrifuge at 16 000 xg for 3 min. 
11. Transfer supernatant to a new tube containing 300 µl isopropanol. Mix by 
inversion. DNA will precipitate as visible strands. 
12. Centrifuge at 16 000 xg for 1 min. 
13. Discard supernatant. 
14. Add 300 µl 70% ethanol to the microcentrifuge tube. 
15. Centrifuge at 16 000 xg for 1 min. 
16.  Discard ethanol and evaporate DNA pellet to dryness for 15 min.  
17.  Add 100 µl DNA Rehydration Solution.  
18. Cap the microcentrifuge tube and incubate for 1 h at 65 °C. 




DNA quantification  
 
Use the Gene Quant spectrophotometer to quantitate DNA and ascertain 
DNA purity. This requires ~ 3 µl of DNA solution. A clean capillary tube is 
essential to obtain accurate results. Blank the instrument on DNA 
Rehydration Solution. 
Nucleic acids have an absorption peak at 260 nm. An absorption coefficient 
exists (different for DNA and RNA), allowing quantitation. In contrast to DNA, 
protein has an absorbance peak at 280 nm. A 260:280 nm absorbance ratio 
of 1.7-2.0 is indicative of good DNA purity (> 80%). A value < 1.7 indicates 
protein contamination.  
Other instruments used to quantify DNA, such as the Nanodrop ND 1000 
(Inqaba), allows an additional measurement at 230 nm, resulting in a 260:230 
nm absorbance ratio. A 260:230 nm absorbance ratio of 1.8 – 2.2 suggests 
DNA purity while a value below 1.8 may reflect the presence of impurities 
such as carbohydrates, salt or phenol which absorb at 230 nm 














Specificity in a non-probe based PCR reaction is critically dependent on 
primer selection. Primers bind to complementary sequences flanking the 
sequence to be amplified. The annealing temperature is the temperature at 
which the primer hybridises to its complementary sequence while the melting 
temperature (Tm) is that at which it dissociates.  
ALAS2 exon 11 primers were designed using Primer Designer for Windows 
(Soft Packaging version 2, Scientific and Education Software). The sequence 
was tested using the BLAST (Basic Local Alignment Search Tool) function on 
NCBI (National Center for Biotechnology Information) Genbank 
(http://www.ncbi.nlm.nih.gov) to confirm forward and reverse primer 
specificity. The sequence complementary to the primer did not contain any 




General guidelines for primer design 
1. Primer length = 17-28 base pairs. Below 17 the annealing temperature 
is too low and above 28 the benefit of added specificity plateaus.   
2. Primer base pair composition = 50-60 % (G+C). This achieves optimal 
primer hybridisation. 
3. The 3' end of the primers should be a G or C, or CG or GC to prevent 
"breathing" of ends and increase the efficiency of priming. 
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4.  Tm may be calculated:   Tm = 4(G+C) + 2(A+T) 
o C. A Tm between 55 
and 80 oC is considered optimal. The Tm of the forward and reverse 
primer should optimally not differ by more than 3 °C. 
5. The optimal annealing temperature will be between 50 and 60 °C and 
may be determined empirically.  
6. Runs of 3 G or C bases at the 3’ end may result in mispriming at GC 
rich sequences (due to stability of annealing) and should be avoided.  
7. Complementarity at the 3’ end between the forward and reverse 
primer may result in primer dimer formation in preference to product, and 
should be avoided.  
8. If possible the sequence complementary to the primer should not 
contain SNP(s) as it may interfere with primer hybridisation.  In the case 
of heterozygosity for a SNP this could result in preferential amplification of 












PCR for ALAS2 Exon 11 





The PCR amplifies a 417 bp fragment consisting of ALAS2 exon 11 and 




Extracted genomic DNA containing ~ 100 ng/µl DNA. Dilute (e.g. <30 ng/µl) 
template may be used but may result in no or weak amplification. 





 Robocycler Gradient 40 Thermal Cycler (Stratagene) 
 Vortex mixer 
 Microcentrifuge 





 5X Green GoTaq Flexi Buffer (Promega) 
 MgCl2  25 mmol/L (Promega) 
 GoTaq DNA Polymerase (Promega) 
 Forward primer  diluted to 25 µmol/L in nuclease free H2O (IDT-Integrated 
DNA Technologies) 
 Reverse primer  diluted to 25 µmol/L in nuclease free H2O (IDT-Integrated 
DNA Technologies) 
 Deoxynucleotide triphosphates (dNTPs) – dATP, dCTP, dTTP, dGTP, 2.5 
mmol/L of each in one solution (Promega) 
 H2O nuclease free (Sabax Water for Injection, Adcock Ingram)  




 Thaw reagents and DNA (except GoTaq DNA Polymerase which is liquid 
at -20 °C due to glycerol content; minimise its exposure to room 
temperature). 
 Vortex and centrifuge reagents and samples. Brief centrifuging in 
between steps is a valuable adjunct in decreasing contamination and 
aiding mixing of reagents. All precautions and risks of contamination 
alluded to during the description of DNA extraction apply. 
 Prepare the reaction mixture shown in Table 12 in a microcentrifuge tube. 
Increase proportionately depending on the number of samples processed. 
Include enough for a blank. Mix well. 
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1 32.8 µl 10 µl 3 µl 1 µl 1 µl 1 µl 0.2 µl 
 
 Pipette 49 µl of the reaction mixture into each PCR microcentrifuge tube. 
Add 1 µl template, vortex briefly and pulse-centrifuge.  
 Overlay with 1 drop of mineral oil (used to prevent evaporation since the 
thermal cycler does not have a heated lid). 
 Transfer to the pre-heated Robocycler. Use a routine program: 
 Initial separation at 95 °C for 1 min            I cycle              
 Separation at 95 °C for 30 sec 
 Annealing at 52 °C for 30 sec                   35 cycles 
 Extension at 72 °C for 20 sec 
 Extension at 72°C for 7 min                       1 cycle 








Polyacrylamide gel electrophoresis for PCR 
product visualisation 





Double stranded DNA is separated in polyacrylamide under non-denaturing 
conditions based on size, with high resolution ability. Polyacrylamide is 
formed by polymerisation of bisacrylamide and acrylamide. Polymerisation is 
aided by ammonium persulphate-induced free radical generation and 
catalysed by TEMED (see later). The phosphate backbone of DNA confers a 
negative charge and migration towards the anode occurs during 
electrophoresis. Fragment size is primarily a function of the number of base 
pairs. Shorter fragments travel faster.  However, size is also influenced by 
conformation, e.g. as conferred by heteroduplexes. Ethidium bromide is a 
positively charged dye that intercalates with double stranded DNA and 
fluoresces under ultraviolet irradiation, allowing post electrophoresis 
visualisation of migrated PCR product.  









 Hoefer vertical electrophoresis unit SE600 Series (Amersham Pharmacia 
Biotechnology) 
 Gel-doc: BTS-20M UVIband version 99 (UVItec) 
 Mixing flasks and cylinder 
 Selection of pipettes and tips 




 TEMED solution (tetramethylethylenediamine) CH3NCH2CH2N(CH3)2  
 Ammonium persulphate 10% (NH4)2S208 
 Acrylamide: bisacrylamide solution: 30% acrylamide (60 g) and 0.8% 
bisacrylamide (1.6 g) up to 200 ml with reagent grade H20. Caution: 
acrylamide in the unpolymerised form is carcinogenic.  
 10X TBE buffer: 108 g Tris ((HOCH2)3CNH2), 55 g boric acid and 9.3 g 
EDTA up to 1 L with reagent grade H20 
 Loading dye: 0.25 g bromophenol blue, 40 g sucrose and 4 ml 0.5 mol/L 
pH 8 EDTA (C10H16N2O8) solution up to 100 ml with reagent grade H20    
 Ethidium bromide solution.  Add 100 µl 1 mg/ml ethidium bromide to 200 
ml with reagent grade H20. Caution: this compound is carcinogenic. 
 100 bp molecular weight marker (Promega). Make a 1:1 dilution of marker 
with loading dye.  







1. Clamp 2 glass plates, separated by spacers, together on top of a gel 
casting stand. This needs to be done securely to prevent gel solution 
leakage during step 4. 
2. Make 4 ml 10X TBE and 8 ml acrylamide: bisacrylamide solution up to 
40 ml with reagent grade H20 in a flask. The final acrylamide 
concentration is 6%. Add 40 µl TEMED and 400 µl ammonium 
persulphate and mix. Immediately proceed to step 3 to prevent 
polymerisation in the flask. 
3. Pour the solution between the glass plates prepared in step 1.  
4. Insert a 20-spacer comb into the top of the gel. 
5. Allow the gel to set for at least 30 min. 
6. Gently remove the comb. 
7. Fit the top electrophoresis tank on top of the vertical glass-gel unit and 
fill the tank with 500 ml 1X TBE buffer (add 50 ml 10X TBE to 450 ml 
reagent grade H20). Ensure that the electrode is covered by buffer. 
8. Prepare samples/blank by adding 10 µl loading dye to 10 µl 
sample/blank. 
9. Load prepared samples using a Hamilton microsyringe. Include 8 µl of 
100 bp marker (1:1 dilution with loading dye). 
10.  Fill the bottom electrophoresis tank with 500 ml of 1x TBE. Carefully 
position the top tank/gel/glass plate unit into the bottom tank. Place lid 
on top electrophoresis tank. Connect the electrodes to power pack 
and run at 270 volt.  The signal indicating “circuit complete” indicates 
that current is flowing through the system. Caution: electrical hazard. 
Allow the gel to run for ~ 1 h, until the loading dye is ~ 1 cm from the 
bottom of the gel. 
11. Discontinue the electrical supply and remove the glass plate/gel unit. 
Stain in ethidium bromide for 10 min. 
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12. Rinse in tap H2O. Transfer the gel to the Gel-doc photographing 
apparatus.  




A visible sample band on gel electrophoresis indicates amplification. 
Correlation with the molecular marker and knowledge of the amplicon size, 
allow confident PCR product identification. The 500 bp marker is brighter 
than the other marker bands. Absence of a sample band indicates failure of, 
or very weak, amplification. 
Non-specific amplification (usually due to an inappropriate PCR annealing 
temperature) may be observed. Primer dimer formation, visible at the bottom 
of the gel due to its small size, may be seen in the blank as a normal 
phenomenon. No other bands should be seen in the blank lane, and if 
present, would indicate contamination.  
In the case of heterozygosity, heteroduplexes may be observed proximal to 
the main PCR amplified band. 
Amplification resolution on a 6% polyacrylamide gel is in the order of 
magnitude of a few base pairs. It may further be improved by loading less 
PCR product, running it for longer or using a higher polyacrylamide 
concentration.  
If a particular mutation creates or abolishes a restriction enzyme site, pre-
digestion of a PCR fragment followed by gel electrophoresis as described 




PCR product purification for sequencing 





After confirmation of correct PCR amplification by gel electrophoresis, 
product is purified prior to sequencing. This excludes shorter DNA fragments 
(below 50 bp), buffer, primers, protein and dyes. DNA binds selectively to a 
silica membrane from which contaminants are washed, followed by elution of 









 Vortex mixer 
 Microcentrifuge 
 A selection of microcentrifuge tubes, dedicated pipettes and filter tips 
 GFX Microspin Columns and Collection tubes (supplied with GFX PCR 
DNA and Gel Band Purification Kit, GE Healthcare) 





 (reagents supplied with GFX PCR DNA and Gel Band Purification Kit, GE 
Healthcare) 
 Capture buffer type 2 
 Wash buffer type 1 




1. Add 500 µl Capture buffer type 2 and 35 µl PCR product to 
microcentrifuge tube, mix and pulse-centrifuge. 
2. Place a Microspin column into Collection tube and pipette mixture from 
step 1 into the column.  
3. Centrifuge at 16 000 xg for 2 min. 
4. Discard flow through from Collection tube and replace the Microspin 
column.  
5. Add 500 µl Wash buffer type 1 to the Microspin column and centrifuge at 
16 000 xg for 2 min. Discard the flow through.  
6. Repeat step 5 once. 
7. Prepare a microcentrifuge tube by cutting the connection between the 
tube and lid. Label lid and tube. Place the Microspin column inside the 
microcentrifuge tube. Discard the Collection tube.  
8. Add 30 µl Elution buffer type 6 to the center of membrane in the Microspin 
column. Incubate for 1 min. 
9.  Centrifuge at 16 000 xg for 1 min and discard the Microspin column.  
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10.  Store eluate at -20 °C. 
11.  Quantitate the purified DNA using the Gene Quant spectrophotometer, 




















Preparation of samples and primers for 
sequencing 





The Sanger reaction is used to perform a unidirectional PCR using purified 
PCR product as template. A mixture of primer, dNTPs and fluorescently 
tagged ddNTPs (dideoxynucleotides – causing chain termination) creates 
sequences of varying length from which the sequence of the template may 
be deduced during capillary zone electrophoresis. Either forward or reverse 
sequences (or both, but not during the same reaction) may be obtained by 
using the appropriate primer. The Central DNA Sequencing Facility at the 
University of Stellenbosch has specific requirements for sample and primer 




1. Dilute an aliquot of primer from 25 µmol/L as used during the initial 
PCR to 1.1 µmol/L. Prepare a clearly labelled microcentrifuge tube 
containing 10 µl primer and seal with parafilm. 
2. Dilute or concentrate (by evaporation on a heating block) purified DNA 
to 8 ng/µl. Prepare a clearly labelled microcentrifuge tube containing 
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You have participated in a number of studies relating to erythropoietic 
protoporphyria. We would like to thank you for your willingness to participate, 
your time and your encouragement. 
After years of work by different investigators, both in South Africa and 
internationally, we have been able to find the porphyria-causing genetic 
mutation which is relevant to you and your family. A mutation is when a change 
occurs in the DNA sequence of a gene (there are a variety of potential reasons 
for such an occurrence), and can therefore be passed on to descendants. 
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Genes carry information required to produce all of the proteins required by the 
body, in a sequence of chemical units called ‘base pairs’. The mutation we have 
discovered is a 4 base pair deletion in the gene coding for a protein called ALA 
synthase. This is a protein involved in haem biosynthesis – haem being required 
for many diverse functions in the body. ALA synthase is the first (of eight) 
enzymes in the haem synthetic pathway, and your family mutation leads to an 
‘overactive’ ALA synthase enzyme. 
Originally it was thought that your family, like the majority of families with 
erythropoietic protoporphyria (EPP), had a mutation in the ferrochelatase gene 
– the gene that encodes the last enzyme in the haem pathway. This is because 
the clinical presentation and the biochemical features (ie the porphyrin 
patterns) of EPP and this new type of porphyria are virtually identical. 
The type of porphyria you have, we have termed ‘X-linked Dominant 
Protoporphyria’. The ferrochelatase enzyme (although normal) is not able to 
cope with the increased quantity of porphyrins manufactured by the overactive 
ALA synthase enzyme. This leads to an accumulation of protoporphyrin in the 
red cells, and in some cases accumulation of protoporphyrin in the liver may lead 
to liver disease. 
The mutation is carried on the X chromosome as a dominant condition, which 
means the daughter of an affected male will always inherit the gene mutation 
and the son of an affected male can never inherit the mutation. Both daughters 
and sons of an affected female have a 50% chance of inheriting the mutation. 
(The explanation for this lies in the fact that males carry one X and one Y 
chromosome, whereas females carry two X chromosomes.) It must be stressed 
that in the case of this particular mutation we are talking of the chances of 
inheriting the mutation in the ALA synthase gene – which does not necessarily 
correlate with the liver disease nor the severity of the condition – these are 
dependant on other factors which we don’t fully understand, nor can we predict. 
This underscores our strong recommendations that you are regularly monitored 
by your physician for liver functions. As iron may play a role in this condition it 
is also advisable that iron levels be monitored and your physician may make 
some recommendations from time to time, based on these levels. 
Please feel free to contact us at any time should you require further 
information or help. As a reference, the following scientific journal article 
describes the science behind this type of porphyria: 
 
Whatley SD,  Ducamp S, Gouya L, Grandchamp B, Beaumont C, Badminton MN, 
Elder GH, Holme SA, Anstey AV,  Parker M, Corrigall AV, Meissner PN, Hift RJ, 
Marsden JT, Ma Y, Mieli-Vergani G, Deybach JC, and Puy H.    C-Terminal 
Deletions in the ALAS2 Gene Lead to Gain of Function and Cause X-linked 
Dominant Protoporphyria without Anemia or Iron Overload. The American 
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